
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            The ‘Informed Matter’ of Gay and Bisexual Men&#x27;s (Potential) Use of HIV Antiretrovirals to Prevent COVID‐19 - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15251C338AEEF613051C330032ECBA40.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374566/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Sociology of Health &amp; Illness">
<meta name="citation_title" content="The ‘Informed Matter’ of Gay and Bisexual Men&#x27;s (Potential) Use of HIV Antiretrovirals to Prevent COVID‐19">
<meta name="citation_author" content="Daniel Storer">
<meta name="citation_author_institution" content="School of Population Health, UNSW Sydney, Sydney, Australia">
<meta name="citation_author_institution" content="School of Law, Society and Criminology, UNSW Sydney, Sydney, Australia">
<meta name="citation_author" content="Dean Murphy">
<meta name="citation_author_institution" content="School of Population Health, UNSW Sydney, Sydney, Australia">
<meta name="citation_author_institution" content="Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Australia">
<meta name="citation_author_institution" content="School of Translational Medicine, Monash University, Melbourne, Australia">
<meta name="citation_author" content="Niamh Stephenson">
<meta name="citation_author_institution" content="School of Population Health, UNSW Sydney, Sydney, Australia">
<meta name="citation_author" content="Garrett Prestage">
<meta name="citation_author_institution" content="Kirby Institute, UNSW Sydney, Sydney, Australia">
<meta name="citation_author" content="Mohamed A Hammoud">
<meta name="citation_author_institution" content="Kirby Institute, UNSW Sydney, Sydney, Australia">
<meta name="citation_publication_date" content="2025 Aug 23">
<meta name="citation_volume" content="47">
<meta name="citation_issue" content="7">
<meta name="citation_firstpage" content="e70078">
<meta name="citation_doi" content="10.1111/1467-9566.70078">
<meta name="citation_pmid" content="40847916">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374566/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374566/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374566/pdf/SHIL-47-0.pdf">
<meta name="description" content="In 2020, there were reports that HIV antiretrovirals, specifically the combination tenofovir disoproxil fumarate and emtricitabine (TDF/FTC), had therapeutic potential for COVID‐19. In the context of scant empirical evidence at the time to confirm ...">
<meta name="og:title" content="The ‘Informed Matter’ of Gay and Bisexual Men&#x27;s (Potential) Use of HIV Antiretrovirals to Prevent COVID‐19">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="In 2020, there were reports that HIV antiretrovirals, specifically the combination tenofovir disoproxil fumarate and emtricitabine (TDF/FTC), had therapeutic potential for COVID‐19. In the context of scant empirical evidence at the time to confirm ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374566/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374566">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1111/1467-9566.70078"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/SHIL-47-0.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374566%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374566/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374566/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374566/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1111/1467-9566.70078" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Sociol Health Illn</button></div>. 2025 Aug 23;47(7):e70078. doi: <a href="https://doi.org/10.1111/1467-9566.70078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1111/1467-9566.70078</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Sociol%20Health%20Illn%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sociol%20Health%20Illn%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sociol%20Health%20Illn%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Sociol%20Health%20Illn%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>The ‘Informed Matter’ of Gay and Bisexual Men's (Potential) Use of HIV Antiretrovirals to Prevent COVID‐19</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Storer%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Daniel Storer</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Daniel Storer</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>School of Population Health, UNSW Sydney, Sydney, Australia</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>School of Law, Society and Criminology, UNSW Sydney, Sydney, Australia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Storer%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Daniel Storer</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Murphy%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Dean Murphy</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Dean Murphy</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>School of Population Health, UNSW Sydney, Sydney, Australia</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Australia</div>
<div class="p">
<sup>
<sup>4</sup>
</sup>School of Translational Medicine, Monash University, Melbourne, Australia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Murphy%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dean Murphy</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stephenson%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Niamh Stephenson</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Niamh Stephenson</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>School of Population Health, UNSW Sydney, Sydney, Australia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stephenson%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Niamh Stephenson</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Prestage%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Garrett Prestage</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Garrett Prestage</span></h3>
<div class="p">
<sup>
<sup>5</sup>
</sup>Kirby Institute, UNSW Sydney, Sydney, Australia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Prestage%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Garrett Prestage</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hammoud%20MA%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Mohamed A Hammoud</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Mohamed A Hammoud</span></h3>
<div class="p">
<sup>
<sup>5</sup>
</sup>Kirby Institute, UNSW Sydney, Sydney, Australia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hammoud%20MA%22%5BAuthor%5D" class="usa-link"><span class="name western">Mohamed A Hammoud</span></a>
</div>
</div>
<sup>5</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="shil70078-aff-0001">
<sup>
<sup>1</sup>
</sup>School of Population Health, UNSW Sydney, Sydney, Australia</div>
<div id="shil70078-aff-0002">
<sup>
<sup>2</sup>
</sup>School of Law, Society and Criminology, UNSW Sydney, Sydney, Australia</div>
<div id="shil70078-aff-0003">
<sup>
<sup>3</sup>
</sup>Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Australia</div>
<div id="shil70078-aff-0004">
<sup>
<sup>4</sup>
</sup>School of Translational Medicine, Monash University, Melbourne, Australia</div>
<div id="shil70078-aff-0005">
<sup>
<sup>5</sup>
</sup>Kirby Institute, UNSW Sydney, Sydney, Australia</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong> Daniel Storer, 
(<span>d.storer@unsw.edu.au</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 25; Received 2024 Oct 25; Accepted 2025 Jul 31; Issue date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Sociology of Health &amp; Illness</em> published by John Wiley &amp; Sons Ltd on behalf of Foundation for the Sociology of Health &amp; Illness.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374566  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40847916/" class="usa-link">40847916</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>In 2020, there were reports that HIV antiretrovirals, specifically the combination tenofovir disoproxil fumarate and emtricitabine (TDF/FTC), had therapeutic potential for COVID‐19. In the context of scant empirical evidence at the time to confirm such an effect, we sought to understand the ways that gay and bisexual men (GBM) made sense of—and embodied—information about HIV antiretrovirals in relation to preventing and/or treating COVID‐19. We conducted interviews with 26 participants between August and November 2020. To understand how information about, and experiences of, consuming antiretrovirals might form part of assemblages of COVID‐19 prevention for GBM in Australia, we draw on Marsha Rosengarten's (2009) concept of ‘informed matter’. ‘Informed matter’ conceptualises the subject (of disease prevention) as involved in a co‐constitutive relationship with the contextual dynamics in which it is situated. Participants drew on their understandings of virology, immunology and pharmaceuticals and experiences with antiretrovirals to form perceptions about their function as therapeutics for COVID‐19. By looking beyond biotechnologies as causal of behaviour, we can avoid unintended moralism in contexts of potentially different use. We argue that using ‘informed matter’ is useful to interrogate, often neglected, complex changes in sex‐associated biotechnologies in complicated informational contexts, such as a global pandemic.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> antiretrovirals, COVID‐19, gay and bisexual men, ‘informed matter’, TDF/FTC</p></section></section><section id="shil70078-sec-0010"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>As early as the end of March 2020, reports surfaced that HIV antiretrovirals may have been effective against the virus SARS‐CoV‐2, potentially preventing severe COVID‐19 disease (Johnson <a href="#shil70078-bib-0028" class="usa-link" aria-describedby="shil70078-bib-0028"><sup>2020a</sup></a><sup>, </sup><a href="#shil70078-bib-0029" class="usa-link" aria-describedby="shil70078-bib-0029"><sup>2020b</sup></a>, 62–63). These reports speculated about the HIV combination drug, tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC),<a href="#shil70078-note-0003" class="usa-link">
<sup>1</sup>
</a> inhibiting replication of SARS‐CoV‐2 in a similar way to another antiviral, remdesivir (Johnson <a href="#shil70078-bib-0029" class="usa-link" aria-describedby="shil70078-bib-0029"><sup>2020b</sup></a>). On 1 May 2020, remdesivir had been granted emergency use authorisation to treat COVID‐19 in the United States (Eastman et al. <a href="#shil70078-bib-0017" class="usa-link" aria-describedby="shil70078-bib-0017">2020</a>). In June 2020, results from an observational study in Spain found rates of COVID‐19 acquisition (and hospitalisation) were lower among people living with HIV (PLHIV) who were taking an antiretroviral combination including TDF than their counterparts on other antiretroviral combinations (Del Amo et al. <a href="#shil70078-bib-0010" class="usa-link" aria-describedby="shil70078-bib-0010">2020</a>). Other observational and case–control studies undertaken in this early pandemic period investigated the association between the severity of COVID‐19 symptoms and TDF/FTC among gay and bisexual men (GBM) (Ayerdi et al. <a href="#shil70078-bib-0002" class="usa-link" aria-describedby="shil70078-bib-0002">2020</a>; Fernandes et al. <a href="#shil70078-bib-0019" class="usa-link" aria-describedby="shil70078-bib-0019"><sup>2020</sup></a>). Despite early promising signs, investigations of TDF/FTC's effectiveness as a prevention of COVID‐19 infection or disease progression produced varying results, with most observing no significant effects (Charre et al. <a href="#shil70078-bib-0009" class="usa-link" aria-describedby="shil70078-bib-0009">2020</a>; Del Amo et al. <a href="#shil70078-bib-0010" class="usa-link" aria-describedby="shil70078-bib-0010"><sup>2020</sup></a>; Delaugerre et al. <a href="#shil70078-bib-0012" class="usa-link" aria-describedby="shil70078-bib-0012"><sup>2022</sup></a>; Ssentongo et al. <a href="#shil70078-bib-0047" class="usa-link" aria-describedby="shil70078-bib-0047"><sup>2021</sup></a>; Verburgh et al. <a href="#shil70078-bib-0053" class="usa-link" aria-describedby="shil70078-bib-0053"><sup>2023</sup></a>). More recently, however, Del Amo et al. (<a href="#shil70078-bib-0011" class="usa-link" aria-describedby="shil70078-bib-0011">2022</a>) found that TDF/FTC significantly reduced the severity of COVID‐19 illness among PLHIV who were virally suppressed and aged over 50 years.</p>
<p>Given the emerging, yet inconclusive, evidence in 2020 about the potential for antiretrovirals to prevent COVID‐19 infection or reduce disease severity, some behavioural surveillance research included questions about the use of TDF/FTC to protect against COVID‐19 (de Sousa et al. <a href="#shil70078-bib-0014" class="usa-link" aria-describedby="shil70078-bib-0014"><sup>2021</sup></a>). A survey conducted among gay men in Brazil and Portugal, commencing on 5 March 2020, found that almost half (46.1%) of participants taking Truvada (the brand name for TDF/FTC) reported they were using it to prevent COVID‐19 (de Sousa et al. <a href="#shil70078-bib-0014" class="usa-link" aria-describedby="shil70078-bib-0014"><sup>2021</sup></a>).</p>
<p>Rather than adjudicate the evidence of TDF/FTC's effectiveness to prevent COVID‐19 or slow its disease progression, our aim in this paper is to interrogate how—in a contested informational context—GBM made sense of, interpreted and embodied information about antiretrovirals' potentials for COVID‐19. We first outline the evolution of antiretrovirals, specifically TDF/FTC, in relation to treating and preventing HIV.</p>
<section id="shil70078-sec-0020"><h3 class="pmc_sec_title">1.1. TDF/FTC: A Brief History</h3>
<p>TDF—brand name Viread—was approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of HIV in adults (U.S. Food and Drug Administration <a href="#shil70078-bib-0049" class="usa-link" aria-describedby="shil70078-bib-0049"><sup>2001</sup></a>), with the approval of FTC—brand name Emtriva—in 2003 (U.S. Food and Drug Administration <a href="#shil70078-bib-0050" class="usa-link" aria-describedby="shil70078-bib-0050"><sup>2003</sup></a>). Both TDF and FTC form part of the reverse transcriptase inhibitor class of antiretrovirals, which work by blocking the production of enzymes that HIV uses to replicate and continue infection of cells (European Medicines Agency <a href="#shil70078-bib-0018" class="usa-link" aria-describedby="shil70078-bib-0018"><sup>2023</sup></a>). Gilead Sciences Inc. combined the two drugs into a single pill, and this formulation—under the brand name Truvada—was approved for HIV treatment in the United States in 2004. TDF/FTC has been widely used in treatment regimens (U.S. Food and Drug Administration <a href="#shil70078-bib-0051" class="usa-link" aria-describedby="shil70078-bib-0051"><sup>2006</sup></a>). However, since the approval of a new formulation of the tenofovir component in 2016, called tenofovir alafenamide fumarate (TAF)—known in its combination with FTC by the brand name Descovy—this formulation is largely used for treatment of HIV in combination therapies (U.S. Food and Drug Administration <a href="#shil70078-bib-0052" class="usa-link" aria-describedby="shil70078-bib-0052"><sup>2016</sup></a>). This shift is mainly due to TDF/FTC's association with renal impairment and reduced bone mineral density (Di Perri <a href="#shil70078-bib-0016" class="usa-link" aria-describedby="shil70078-bib-0016"><sup>2021</sup></a>). In 2008, TDF was also approved for the treatment of chronic hepatitis B in the United States (Gilead <a href="#shil70078-bib-0021" class="usa-link" aria-describedby="shil70078-bib-0021">2008</a>) and Australia (PBS <a href="#shil70078-bib-0036" class="usa-link" aria-describedby="shil70078-bib-0036"><sup>2009</sup></a>).</p>
<p>Since the 1980s, antiretrovirals have also been used to prevent HIV infection after exposure to the virus (Beekmann and Henderson <a href="#shil70078-bib-0004" class="usa-link" aria-describedby="shil70078-bib-0004">2014</a>). TDF/FTC has been listed as a preferred regimen for this purpose—referred to as HIV post‐exposure prophylaxis (PEP)—since 2005 by the U.S. Centers for Disease Control and Prevention (Panlilio et al. <a href="#shil70078-bib-0035" class="usa-link" aria-describedby="shil70078-bib-0035">2005</a>) and is the recommended two‐drug regimen in Australian guidelines (ASHM <a href="#shil70078-bib-0001" class="usa-link" aria-describedby="shil70078-bib-0001"><sup>2023</sup></a>). The first evidence of TDF/FTC's effectiveness as HIV pre‐exposure prophylaxis (PrEP) among cisgender men who have sex with men (MSM) and trans women was published in 2010 (Grant et al. <a href="#shil70078-bib-0022" class="usa-link" aria-describedby="shil70078-bib-0022">2010</a>). Even prior to publication of these findings, small numbers of gay men had been using antiretrovirals off‐label (for a purpose not indicated on the medications' registered approval) for HIV treatment or prevention after exposure (Kellerman et al. <a href="#shil70078-bib-0030" class="usa-link" aria-describedby="shil70078-bib-0030">2006</a>; Krakower et al. <a href="#shil70078-bib-0031" class="usa-link" aria-describedby="shil70078-bib-0031"><sup>2012</sup></a>; Zablotska et al. <a href="#shil70078-bib-0056" class="usa-link" aria-describedby="shil70078-bib-0056"><sup>2013</sup></a>). TDF/FTC and TAF/FTC have been approved for use as PrEP by regulatory authorities in many countries. In Australia, TDF/FTC is still favoured for PrEP, as it is the only antiretroviral combination subsidised by the national health insurance scheme.</p>
<p>The use of PrEP by GBM in Australia is very high, having increased from an estimated 0.9% in 2014 to 66.8% in 2023 (Broady et al. <a href="#shil70078-bib-0006" class="usa-link" aria-describedby="shil70078-bib-0006">2024</a>, 36). In addition, the proportion of HIV‐positive men on antiretroviral treatment increased from 85.3% in 2014 up to 96.0% in 2023 (Broady et al. <a href="#shil70078-bib-0006" class="usa-link" aria-describedby="shil70078-bib-0006">2024</a>, 33). The high use of antiretrovirals for HIV treatment and prevention among GBM in Australia provides a concentrated context for investigating cultures of antiretroviral use (Murphy et al. <a href="#shil70078-bib-0034" class="usa-link" aria-describedby="shil70078-bib-0034">2024</a>), including throughout the COVID‐19 pandemic.</p></section><section id="shil70078-sec-0030"><h3 class="pmc_sec_title">1.2. Antiretroviral Assemblages</h3>
<p>Assemblage approaches, following Deleuze and Guattari (<a href="#shil70078-bib-0013" class="usa-link" aria-describedby="shil70078-bib-0013">1988</a>), have been influential in helping scholars think about the nonlinear connections between bodies, HIV drugs and other entities and how they come together to produce effects (Gagnon and Holmes <a href="#shil70078-bib-0020" class="usa-link" aria-describedby="shil70078-bib-0020">2016</a>). That is, rather than one thing affecting another, a multitude of ‘actors’ influence <em>each other</em> throughout their interactions.</p>
<p>In the field of HIV, assemblage thinking has been used to interrogate traditional understandings of the effects of drugs on bodies. Assemblage approaches to exploring antiretroviral effects have included studies on the following: the complexities of PrEP clinical trials (Rosengarten and Michael <a href="#shil70078-bib-0043" class="usa-link" aria-describedby="shil70078-bib-0043"><sup>2009b</sup></a>); the expectations of PrEP among scientific stakeholders involved in PrEP trials (Rosengarten and Michael <a href="#shil70078-bib-0042" class="usa-link" aria-describedby="shil70078-bib-0042"><sup>2009a</sup></a>); the configuration of potential users (Holt <a href="#shil70078-bib-0026" class="usa-link" aria-describedby="shil70078-bib-0026">2015</a>) and the experience of side effects (Gagnon and Holmes <a href="#shil70078-bib-0020" class="usa-link" aria-describedby="shil70078-bib-0020">2016</a>). Research after TDF/FTC became widely used for HIV prevention has paid similar attention to the relational processes between users and these biotechnologies (Brown and Di Feliciantonio <a href="#shil70078-bib-0007" class="usa-link" aria-describedby="shil70078-bib-0007"><sup>2022</sup></a>; Murphy et al. <a href="#shil70078-bib-0034" class="usa-link" aria-describedby="shil70078-bib-0034"><sup>2024</sup></a>; Smith et al. <a href="#shil70078-bib-0044" class="usa-link" aria-describedby="shil70078-bib-0044"><sup>2023</sup></a><sup>, </sup><a href="#shil70078-bib-0045" class="usa-link" aria-describedby="shil70078-bib-0045"><sup>2022</sup></a>; Young and Boydell <a href="#shil70078-bib-0055" class="usa-link" aria-describedby="shil70078-bib-0055"><sup>2023</sup></a>). In this paper, we use assemblage thinking, specifically drawing on Rosengarten's (<a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>) conceptualisation of ‘informed matter’, to investigate the contexts and relationships of GBM's antiretroviral consumption during the first year of the COVID‐19 pandemic.</p></section><section id="shil70078-sec-0040"><h3 class="pmc_sec_title">1.3. The ‘Informed Matter’ of HIV Prevention</h3>
<p>By the early 2000s, highly active antiretroviral therapy (HAART) had become the standard of care for PLHIV, and ‘science gave promise that infection rates resulting from [condomless sex] could be reduced as a consequence of reduced individual viral loads’ (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 59). However, concerns had emerged about how gay men were changing their sexual behaviour in light of this promise. These changes included reducing condom use based on information about the effectiveness of antiretrovirals in suppressing viral replication (attributed to ‘treatment optimism’, an explanation that did not grapple with shifts in possibilities for the prevention of HIV transmission). This positioned changes in HIV prevention behaviours as potentially ‘irresponsible’.</p>
<p>To break up this unidirectional (and potentially moralising) approach to how gay men were receiving and putting to use this new information about antiretrovirals, Rosengarten (<a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>) developed the concept of ‘informed matter’. Drawing on the work of Barry (<a href="#shil70078-bib-0003" class="usa-link" aria-describedby="shil70078-bib-0003">2005</a>), ‘informed matter’ reconceptualised the gay male subject of HIV prevention discourse. It replaced a subject who was understood as autonomous and agentic (and assumed, therefore, to use information about HIV risk responsibly) with a subject conceptualised as both embodied and involved in a co‐constitutive relationship with the ‘dynamic context’ (61–2) in which he was situated. This new subject of HIV prevention was one that was technologised through antiretroviral drugs and viral load testing technologies or, as Rosengarten argued, through the traffic between information and flesh. This ontological shift meant abandoning the conventional distinction between human and biotechnology (as described above). It also, as Rosengarten argued, questioned the distinction between human subject and material body that was customary in HIV prevention (<a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 61).</p>
<p>‘Informed matter’ moves beyond considering changes in gay men's approaches to sex without condoms as ‘bad’ and in need of intervention. Rather, it focuses on how more than biotechnologies are involved when gay men practise HIV prevention, including how they interpret and implement new information:</p>
<blockquote class="text-italic"><p>Rather than simply accept the general presumption of the HIV prevention education field that human practices are informed by knowledge and, therefore, one simply needs more effective knowledge, draw[ing] attention to an historico‐material process that […] can be seen as embodied in the target. This recasting of the target of prevention provides a subtle but strategic alternative to the more usual viewing of persons as merely acting in response <em>to</em>, and subsequent to the event <em>of</em>, an intervention. (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 14 original emphasis)</p></blockquote>
<p>The aim of Rosengarten's intervention was to interrupt the potential moralisation of emerging HIV prevention strategies as the product of ‘flawed’ engagements with new biotechnologies. Rosengarten challenged this linear explanation with an understanding of decision‐making about HIV prevention as intertwined with these biotechnologies, different sources of knowledge and the context in which these are brought together. That is, decision‐making about HIV prevention is intertwined with these biotechnologies, different sources of information and knowledge, and the context in which they come together, that is, antiretrovirals and histories of HIV prevention and treatment. Other researchers have worked to intervene in the potentially moralising ways of thinking about how GBM develop behaviours around new HIV prevention technologies (Race <a href="#shil70078-bib-0038" class="usa-link" aria-describedby="shil70078-bib-0038">2015</a>; Spieldenner <a href="#shil70078-bib-0046" class="usa-link" aria-describedby="shil70078-bib-0046"><sup>2016</sup></a>), including throughout the COVID‐19 pandemic (Hakim et al. <a href="#shil70078-bib-0023" class="usa-link" aria-describedby="shil70078-bib-0023">2022</a>). However, using ‘informed matter’ situates the practices and perceptions of GBM within the historical context in which they are occurring. Paying attention to this historicity involves examining how context contributes to the relations between actors (human and nonhuman) in the assemblage. By interrogating how biotechnologies are used, how knowledge is mobilised in these uses and where and how they influence sexual practice, we may resist conventional, linear or causal claims about the relationships between these technologies, behaviours and risk reduction strategies.</p>
<p>Although Rosengarten was writing in a time when HIV treatments and technologies were altering gay men's cultures of prevention, our analysis considers how antiretrovirals that are already in use—and in bodies—to treat and prevent HIV are <em>informing</em> the potential for prevention in the context of a different virus. This new context involves processes where GBM and antiretrovirals come together with new information and produce something different, a COVID‐19 prevention assemblage that is informed by a history of HIV treatment and prevention. As we will demonstrate, similar modes of framing responsible/correct or irresponsible/incorrect behaviour and antiretroviral use were also at play in 2020. Using ‘informed matter’ has the potential to uncover how information about TDF/FTC and its potential for COVID‐19 contributed to the <em>process</em> of making GBM through discourses of COVID‐19 prevention.</p></section></section><section id="shil70078-sec-0050"><h2 class="pmc_sec_title">2. Methods</h2>
<p>Our study was designed at a time when certain HIV antiretrovirals (the protease inhibitors lopinavir and ritonavir (Cao et al. <a href="#shil70078-bib-0008" class="usa-link" aria-describedby="shil70078-bib-0008">2020</a>) and other broad‐spectrum antivirals, such as remdesivir (Eastman et al. <a href="#shil70078-bib-0017" class="usa-link" aria-describedby="shil70078-bib-0017">2020</a>)) were being investigated as potential treatments for COVID‐19. An early study indicated that TDF/FTC might be effective (Del Amo et al. <a href="#shil70078-bib-0010" class="usa-link" aria-describedby="shil70078-bib-0010">2020</a>). Our decision to ask about knowledge and use of antiretrovirals for COVID‐19 was also influenced by other research among GBM that included questions about this use (see de Sousa et al. <a href="#shil70078-bib-0014" class="usa-link" aria-describedby="shil70078-bib-0014"><sup>2021</sup></a>; Sousa et al. <a href="#shil70078-bib-0015" class="usa-link" aria-describedby="shil70078-bib-0015"><sup>2020</sup></a>; Reyniers et al. <a href="#shil70078-bib-0040" class="usa-link" aria-describedby="shil70078-bib-0040"><sup>2021</sup></a>; Torres et al. <a href="#shil70078-bib-0048" class="usa-link" aria-describedby="shil70078-bib-0048"><sup>2021</sup></a>).</p>
<p>We conducted qualitative semi‐structured interviews with GBM. Participants were recruited from a larger study on the impacts of the COVID‐19 pandemic, where they were asked to indicate if they were willing to participate in an interview. Some sociodemographic characteristics were prioritised during participant selection (i.e., aged 25 years or under, HIV serostatus, country of birth and visa/resident status) to ensure strong representation. Others were monitored but not actively prioritised (i.e., sexual activity, PrEP use, composition of household, relationship status, ethnic background, education level, residential location and employment status) (see Table <a href="#shil70078-tbl-0001" class="usa-link">1</a>). Eligibility for the larger study is discussed elsewhere (Hammoud et al. <a href="#shil70078-bib-0024" class="usa-link" aria-describedby="shil70078-bib-0024">2020</a>). All participants provided written consent prior to the interview. Ethical approval was granted by the Human Research Ethics Committee of UNSW Sydney.</p>
<section class="tw xbox font-sm" id="shil70078-tbl-0001"><h3 class="obj_head">TABLE 1.</h3>
<div class="caption p"><p>Participant characteristics at initial interview.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">
<em>N =</em> 26</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Age in years</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
<td align="center" valign="top" rowspan="1" colspan="1">23–77</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean</td>
<td align="center" valign="top" rowspan="1" colspan="1">43.7</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Gender</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male (cis)</td>
<td align="center" valign="top" rowspan="1" colspan="1">26</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sexuality</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gay</td>
<td align="center" valign="top" rowspan="1" colspan="1">24</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bisexual/pansexual</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Country of birth</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Australia</td>
<td align="center" valign="top" rowspan="1" colspan="1">18</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other country</td>
<td align="center" valign="top" rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Education level</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">High school</td>
<td align="center" valign="top" rowspan="1" colspan="1">5</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Trade certificate</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">University degree</td>
<td align="center" valign="top" rowspan="1" colspan="1">18</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">HIV status</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV positive (on antiretrovirals)</td>
<td align="center" valign="top" rowspan="1" colspan="1">7</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV negative (using PrEP)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV negative (not currently using PrEP)<a href="#shil70078-note-0002" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">6</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV negative (never used PrEP)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/shil70078-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="shil70078-note-0002">
<sup>
<sup>a</sup>
</sup><p class="display-inline">This includes participants who had a history of using PrEP but were not using it at the time of interview.</p>
</div></div></section><p>DS conducted interviews between August 2020 and November 2020 by telephone or videoconference. Interviews focused on how the pandemic impacted participants' mental health and wellbeing, relationships and sex lives. For the latter, we asked about sexual practices and drug use since the start of the pandemic (including during stay‐at‐home orders), HIV care and prevention, and prevention of sexually transmitted infections (STIs). Given the information about antiretrovirals circulating at the time (described above) and that most participants were already taking antiretrovirals for HIV treatment or prevention, participants were also asked about their perspectives on TDF/FTC's potential uses for COVID‐19. Participants were asked, ‘What do you think about using the drug used for PrEP to reduce your risk of getting COVID?’. Interviews lasted ∼79 min, ranging from 49 to 123 min, were audio‐recorded, professionally transcribed, de‐identified and checked for accuracy. To ensure participants' confidentiality, each participant chose a pseudonym for research outputs.</p>
<p>Overall, we conducted interviews with 26 participants. All participants identified as cis men, most were gay and seven were living with HIV (see Table <a href="#shil70078-tbl-0001" class="usa-link">1</a>). Most HIV‐negative participants were using—or had previously used—PrEP, and all participants with HIV were on treatment (see Table <a href="#shil70078-tbl-0001" class="usa-link">1</a>). The majority (three‐quarters) of participants had an awareness of the possibility of TDF/FTC being used to prevent COVID‐19. The level of interest in or entertainment of the idea differed across participants who had an awareness. Two participants had no prior awareness, and for the remaining four, it was unclear whether they had prior awareness from their answers.</p>
<p>Throughout this paper, we are guided by reflexive thematic analysis (Braun and Clarke <a href="#shil70078-bib-0005" class="usa-link" aria-describedby="shil70078-bib-0005">2019</a>, 2021). This approach required us to develop themes that were not simply categories of broad topics or subject domains but to find recurring meanings across interview transcripts, ‘patterns of shared meaning, underpinned by a central meaning‐based concept’ (Braun and Clarke <a href="#shil70078-bib-0005" class="usa-link" aria-describedby="shil70078-bib-0005">2019</a>, 593). However, the aim of this approach is not to be completely descriptive but to be able to adapt the process that makes sense for the project. To organise interview transcripts, DS developed a coding framework based on topics covered in the study's interviews. By organising the data in this way, it provided a subset of data by topic area. This allowed DS to work with a smaller section of data (in this case, sections of the data that discussed TDF/FTC and COVID‐19) to develop themes. Data were organised using QSR NVivo (12.6.1.970). We explore the historical relationship GBM have with antiretrovirals and how this relationship <em>informs</em> speculation about the possible effectiveness of these same drugs for COVID‐19 using ‘informed matter’.</p></section><section id="shil70078-sec-0060"><h2 class="pmc_sec_title">3. Findings</h2>
<p>We established three themes about how participants made sense of TDF/FTC's use for preventing COVID‐19 infection or reducing the severity of illness. First, participants used their knowledge of viral transmission and replication (of HIV and SARS‐CoV‐2) and understandings of how TDF/FTC (and other antiretrovirals) work within bodies. Second, participants drew on their experiences of using antiretrovirals for HIV prevention and treatment, including dosing practices. Finally, participants speculated on the potential for knowledge about TDF/FTC and COVID‐19 to influence behaviour, particularly among gay men using PrEP.</p>
<section id="shil70078-sec-0070"><h3 class="pmc_sec_title">3.1. Using Virological, Immunological and Pharmaceutical Knowledge</h3>
<p>By analysing how participants engaged with virological and pharmaceutical information, we see how they positioned TDF/FTC's potential role against COVID‐19. This positioning provides a way of identifying where knowledge about HIV and COVID‐19 dis/connects for participants. Bryan, an HIV‐negative bisexual man in his 70s, had used PrEP prior to the COVID‐19 pandemic and saw TDF/FTC's antiviral abilities as indiscriminate:</p>
<blockquote class="text-italic"><p>I mean how it [TDF/FTC] operates would make me think that it would make me less likely to get COVID. Or for COVID to go anywhere. You know, I don’t see that it would necessarily discriminate between an HIV virus [sic] and a COVID virus [sic], […] I wouldn’t be surprised if it did confer some prophylaxis there.</p></blockquote>
<p>As noted earlier, Bryan—as with all participants—was recruited from a wider project that included questions about the use of TDF/FTC for COVID‐19. As with Holt's (<a href="#shil70078-bib-0025" class="usa-link" aria-describedby="shil70078-bib-0025">2013</a>) account of how surveillance activities, like survey participation, mediate the imaginaries of gay men, here the activities within the survey from which participants were recruited and the questions they were asked in their interview for this study may mediate their imaginaries of what TDF/FTC can be. These kinds of research questions prompt participants to reflect on their own relationships with biotechnologies, including knowledge and embodied practices. A history of personal use of TDF/FTC and engagement in research shaped Bryan's conclusion that TDF/FTC may have a role in preventing COVID‐19 infection, much as this antiretroviral combination has done to prevent the acquisition of HIV. Bryan's account highlights how relationships with antiretrovirals and understandings of the relationship between the body and substances—referred to as pharmacokinetics and pharmacodynamics—allow for the possibility that TDF/FTC could be a prophylaxis for both HIV and COVID‐19.</p>
<p>Other participants compared their understandings of SARS‐CoV‐2 and HIV in their accounts, including the structure and transmission routes of the two viruses. Charlie, a gay man living with HIV in his 50s who, prior to being interviewed, had not heard about the potential use of TDF/FTC for COVID‐19, drew on his knowledge of viral transmission to question TDF/FTC's likely effectiveness against SARS‐CoV‐2:</p>
<blockquote class="text-italic"><p>I don’t see any connection between Truvada [TDF/FTC] and preventing a COVID infection. Considered we’re talking droplets<a href="#shil70078-note-0004" class="usa-link">
<sup>2</sup>
</a> rather than blood, semen, whatever, as well, yeah. I don’t see the connection.</p></blockquote>
<p>Notably, information about HIV transmission routes has been emphasised through health promotion interventions targeting gay men over several decades, highlighting the specific sexual practices required for transmission. Although SARS‐CoV‐2 can also be transmitted through direct physical contact between people, transmission occurs in <em>indirect</em> ways as well via contaminated objects (fomites), droplets sprayed onto mucous membranes and inhalation of <em>aerosols</em> (although airborne transmission was much discussed and disputed early in the pandemic). With Charlie's understanding of TDF/FTC as a biotechnology specifically for treating and for preventing the transmission of HIV to sexual partners, it was implausible that the same drug could have an effect against COVID‐19 (or SARS‐CoV‐2).</p>
<p>To provide another example of someone thinking about TDF/FTC as the wrong tool for COVID‐19, Joseph says, ‘[i]t's like trying to catch a frog with a fly swatter.’ Joseph clarifies his thoughts using an analogy:</p>
<blockquote class="text-italic"><p>If you have any understanding of what the HIV virus [sic] looks like and does, and binds to, and any understanding of what a coronavirus looks like and binds to, it’s pretty obvious that, unless you have some weird thing going on, it’s [TDF/FTC] probably not going to help. […] People think that, you know, if it’s antiviral, it’s antiviral. […] It’s like saying all flour is the same. […] It’s a bit like you know, I want to make a flat bread. Let me use self‐raising flour. And then you’re disappointed when you don’t have flat bread.</p></blockquote>
<p>Joseph's account draws on knowledge about the pharmacological activity of antiretrovirals against viruses, knowledge that goes beyond traditional prevention messaging for both HIV and COVID‐19. Joseph's comparison of the viruses by morphology may be influenced by Australian public health officials' and media's use of images of the SARS‐CoV‐2 particle to visualise transmission and replication and later to describe the function of vaccines. However, the comparison that Joseph made forecloses on the possibility that TDF/FTC may have broad‐acting capabilities and relies on knowledge that (antiretro)viral medications only work for a specific purpose, even as science was investigating broad‐based applications of a range of HIV antiretrovirals, including TDF/FTC (e.g., Ayerdi et al. <a href="#shil70078-bib-0002" class="usa-link" aria-describedby="shil70078-bib-0002"><sup>2020</sup></a>; Charre et al. <a href="#shil70078-bib-0009" class="usa-link" aria-describedby="shil70078-bib-0009"><sup>2020</sup></a>). Notably, this move to the molecular goes beyond making a distinction between sexual encounters and signals that the informational context in which participants are <em>becoming</em> requires us to look beyond, but not exclude, the role of sex.</p>
<p>The accounts above operate in what can be considered ‘part of the making of a heterogenous technologized field’ (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 77). That is, different articulations of virological, immunological and pharmaceutical knowledge—whether this knowledge is correct or not—can be framed as ontological differences that are shaped by informational contexts pertaining to both HIV and COVID‐19. Participants were not asked to elaborate further on their understandings of how antiretrovirals act on/against HIV and the connections they make, or do not, with COVID‐19. However, they may have drawn on their understandings—as subjects of decades of HIV prevention, which includes messaging about shared responsibility, behaviour change (using condoms) and biomedical interventions (testing, PEP, undetectable viral load and PrEP)—of how the immune system responds to a viral challenge and, specifically, the role of CD4 cells in this response.<a href="#shil70078-note-0005" class="usa-link">
<sup>3</sup>
</a> This knowledge of the immune system response—particularly among PLHIV, who have the levels of these cells in their body tested to understand HIV progression—could contribute to perceptions of TDF/FTC's (in)ability to produce bodily effects for COVID‐19. This knowledge could be understood as what Rosengarten (<a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>) calls the ‘traffic’ between information and flesh. That is, rather than thinking about bodies and interventions as bifurcated and marking out their difference—bodies responding to interventions—‘traffic’ denotes the flow of information between bodies and interventions as mutual. Constituted as subjects of HIV prevention and treatment—where information was historically demanded and often resulted in dense exchanges between people affected by HIV and science—the accounts above provide ways of allowing ‘movement [in understandings of HIV and COVID‐19] that helps constitute their difference as much as dissolve it’ (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 17). In other words, we can recognise that interventions, knowledge about them and relationality between actors can produce something more than cause and effect. Seen through this lens, Charlie and Joseph's accounts suggest that this ‘traffic’ between information and flesh is constitutive of divergent thinking about the role of TDF/FTC in COVID‐19 prevention.</p></section><section id="shil70078-sec-0080"><h3 class="pmc_sec_title">3.2. Informed by Experience</h3>
<p>Understandings of viral replication and its prevention, explored above, influenced how participants discussed the work of antiretrovirals within bodies. Additionally, embodied experiences and practices of using antiretrovirals provided participants with important contextual knowledge about TDF/FTC and COVID‐19. This included the bodily experiences of side effects, dosing practices, viral suppression and protection from HIV. For participants like Imran, a gay man in his 30s, making sense of questions about TDF/FTC's therapeutic potential for COVID‐19 entailed an assemblage of bodies, drugs, virus and knowledge that was different from but informed by HIV assemblages. Imran's account draws on his embodied knowledge of TDF/FTC use—in particular, dosing practices, (lack of) side effects and access—to allow for the possibilities of TDF/FTC for COVID‐19:</p>
<blockquote class="text-italic"><p>I don’t think there is enough science behind it, or data behind it, but, having said that, it’s like taking a vitamin tablet: you know, it doesn’t harm you, right? You might as well just take it. I don’t think the general population should take it, but I had it at home. Like it’s not like I had to go out of my way, go see a doctor or go to a pharmacy to get said medication, or I didn’t know what the side effects were. […] I would have been on it anyway. So, I just took it as an additional, precautionary thing.</p></blockquote>
<p>Imran's declaration that there is not ‘enough’ empirical evidence to support the use of the antiretroviral for COVID‐19, the foregrounding in his account suggests some awareness of the available research. Armed with knowledge of TDF/FTC's effects within his own body and an understanding of limited evidence for the benefits of vitamins, TDF/FTC becomes harmless and mundane (Smith et al. <a href="#shil70078-bib-0044" class="usa-link" aria-describedby="shil70078-bib-0044">2023</a>). Although there may not be any significant benefit, Imran knew TDF/FTC ‘doesn't harm you’; he had a supply on hand, and, if he had been having sex, the drug was already in his body. This openness would not be possible without the experience of using TDF/FTC. Although he does not specify why he suggested against the general population using TDF/FTC for COVID‐19, this emphasis could be due to the lack of evidence from clinical trials to support its use for COVID‐19 or the impact it may have on the availability for people who use TDF/FTC to prevent HIV, as occurred with hydroxychloroquine.</p>
<p>Similarly, Tristan, a man living with HIV in his 50s who was aware of TDF/FTC as a possible preventative for COVID‐19, stated, ‘I was really interested in that and I started reading a lot about it’, and he also drew on his experience with antiretrovirals for HIV treatment:</p>
<blockquote class="text-italic"><p>When I first looked at the virus [SARS‐CoV‐2] and realised that it was an RNA and DNA virus, I thought, ‘Hang on. I bet some of the HIV antiretrovirals would be of assistance’. I did look into some of the use of Truvada [brand name TDF/FTC] and also, I think, Biktarvy [brand name for the antiretroviral combination containing the integrase inhibitor, bictegravir, as well as FTC TAF], was also mentioned. […] I don’t know whether it would have any prophylactic effect on me. […] I have had Truvada; I’m not [using it] at the moment but I think the ingredients in Truvada are in my current medication anyway.</p></blockquote>
<p>Tristan's knowledge base has been built up through his engagement with HIV prevention prior to, and 11 years since, seroconversion. However, his perception was that if TDF/FTC, or other antiretrovirals, did have prophylactic capacity against COVID‐19, he was sceptical of the effectiveness for him personally. Tristan remarked further on the extensiveness of HIV research and the benefits it may have for SARS‐CoV‐2 and other infectious diseases, ‘I started to think that the 30‐plus years of investigations into virology and HIV studies will be of benefit in the treatment and vaccines for this coronavirus.’ This hopefulness for HIV science and COVID‐19 is incongruous with Tristan's pessimism for the benefit of antiretrovirals to himself.</p>
<p>A lack of scientific evidence to suggest a preventative effect of TDF/FTC against COVID‐19 ruled out any meaningful reason to consider the medication for many participants (although, paradoxically, there was evidence to suggest a reduction in severity of COVID‐19 infection among PLHIV aged over 50 (Del Amo et al. <a href="#shil70078-bib-0011" class="usa-link" aria-describedby="shil70078-bib-0011">2022</a>)). In contrast to Tristan, because of this lack of evidence to suggest a broader association, Brandon, another man aged in his 50s living with HIV, suggested that something intrinsic to an individual might assist with any protective quality that antiretrovirals could have for COVID‐19:</p>
<blockquote class="text-italic"><p>I mean I read a lot about what’s going on with the HIV treatment situation and I ask a lot of questions [of my healthcare providers]. And it’s just, there’s no studies that say that HIV medication has any real association with COVID at all. It might have an association with an individual who’s taking it, but it has got nothing to do with COVID. And, if you think you’re going to take it to stop COVID, forget it.</p></blockquote>
<p>Like Tristan, Brandon's engagement with HIV treatment fostered a curiosity about the advancement of the field and, in particular, how this was unfolding throughout the COVID‐19 pandemic. Although Brandon was firm that there was no ‘real association’ between antiretrovirals providing protection against COVID‐19 based on his investigations, his account left open the possibility of protective associations between antiretrovirals and COVID‐19 for individuals.</p>
<p>Taken together, Imran's, Tristan's and Brandon's accounts blur the lines of how drug effectiveness is conceived when accounting for embodied experiences and practice. The dynamism of knowledge processes in these accounts highlights the ‘coextensive relation between information and flesh’ (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 5). Information and flesh (the body and the processes that occur within, on and in relation to it) become intertwined with understandings of antiretrovirals within the body, on viruses and knowledge that contribute to perceptions and decisions. Understanding the nuanced ‘traffic’ of informational effects mends the bifurcation of information and flesh and opens up what is possible to know about how biotechnologies become material within, and in relation to, experience.</p></section><section id="shil70078-sec-0090"><h3 class="pmc_sec_title">3.3. Misinforming (Potential) Behaviour</h3>
<p>Conventional framings of knowledge can be used to instil a sense of authority, particularly when it concerns the potential to contribute to changes in behaviour that are viewed as responsible/correct or irresponsible/incorrect. For some participants, their accounts emphasised the impact that the potential use of TDF/FTC for COVID‐19 might have on the behaviour of GBM in general. At times, sources of knowledge and/or advice were contrasted against each other to highlight what was deemed (un)trustworthy and influential:</p>
<blockquote class="text-italic"><p>If it was said and driven by the chief health officer, and published in a peer‐reviewed article, I’d listen to it. But, if it’s just some gay people trying to find an excuse, I would not listen to it. […] Like, if the [state] government said, ‘PrEP reduces risk of getting COVID‐19,’ I’d be like, ‘Oh okay, sure. Let’s do it’. But, if it’s just a gay wives' tale like, come on. (Harry, 20s, HIV negative, had never used PrEP)</p></blockquote>
<p>Harry had an awareness of the potential of TDF/FTC for COVID‐19, and in his account, he made clear that the chief health officer<a href="#shil70078-note-0006" class="usa-link">
<sup>4</sup>
</a> or evidence ‘published in a peer‐reviewed article’ would have more salience for behaviour change concerning PrEP than ‘if it's just gay people trying to find an excuse’. Harry's framing conjures notions of ‘gay men as selfishly, sometimes murderously, hedonistic, reckless and irresponsible’ (Hakim et al. <a href="#shil70078-bib-0023" class="usa-link" aria-describedby="shil70078-bib-0023">2022</a>, 290), creating ‘gay wives’ tales’—a kind of misinformation—to justify behaviour. Through Harry's account, we gain insights into how gay men themselves—alongside policymakers and public health authorities—participated in discourses that relied on normative framings of biotechnologies—framings critiqued by Rosengarten—in which biotechnologies are preformed objects that are taken up in either responsible/correct or irresponsible/incorrect ways.</p>
<p>Discussion of TDF/FTC for COVID‐19 as misinformation was articulated through several participant accounts and was usually framed as circulating through GBM social circles to fit narratives for its effectiveness (‘gay wives’ tales' a la Harry). The circulation of this ‘misinformation’ was something Marcus, a gay man living with HIV in his 30s, recounted trying to dispel in his role as a community health worker:</p>
<blockquote class="text-italic"><p>When China did treat people with that particular kind of [antiretroviral], the [HIV negative] gays were [thinking], ‘Oh my God! We’re PrEPs’, you know. […] But no, I think people in the community are very clear about that. Occasionally, I do get asked questions about, around, that. I’m just like, ‘Oh, no, no. That’s just a meme. That’s not real’.</p></blockquote>
<p>Marcus recounted challenging community members' speculation about PrEP (i.e., TDF/FTC) having some effect against COVID‐19 by trying to convince them it is ‘not real’ and is ‘just a meme’—referencing its slip into social media feeds—signalling that it is not to be taken seriously. Marcus's actions were aimed at preventing behaviour he characterised as ‘incorrect’. His strategy relied on providing information that would discourage ‘incorrect’ behaviour and shut down what Rosengarten calls ‘inventive approach[es]’ (2009, 73) to risk reduction. The discouragement of diverse approaches to risk reduction reinforces dominant ideals of prevention and behaviour while inhibiting creativity, irrespective of the success of strategies. Like Harry's positioning of gay men as providing misinformation, in Marcus's account biotechnologies are framed as causal of behaviours, a representation that contributes to conventional ways of thinking about GBM's relationships with biotechnologies (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 13).</p>
<p>Understanding the relationship between interventions and the groups for whom they were intended involves investigating how knowledge becomes entangled in discourses of correct/incorrect social and sexual behaviour. While our goal throughout this paper has been to think beyond these binaries, to disregard them where they exist misses crucial understandings of how biotechnologies and knowledge become material through users' experiences in situations where sex is seen as causing disease (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 64). The conflation implicit in Harry’s and Marcus’s accounts are spectres of when ‘HIV […] bore a prior investment in an already pathologized gay sexuality, an investment in a thinly guised claim of gay sexuality as not “right”’ (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 8) in the COVID‐19 pandemic context. That is, men who imagined the possibilities of TDF/FTC for COVID‐19 and sex were cast as threatening perceptions of ‘homonormative respectability’ (Hakim et al. <a href="#shil70078-bib-0023" class="usa-link" aria-describedby="shil70078-bib-0023">2022</a>, 294). This evokes representations of GBM imagined as engaging in wanton behaviour and as blameworthy for ongoing transmission and the extension of restrictions on movement.</p></section></section><section id="shil70078-sec-0100"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>Our analysis has considered the contributors to how GBM in Australia made sense of antiretrovirals as a biotechnology for COVID‐19. We explored how virological, immunological and pharmaceutical knowledge was leveraged, how experiences of using antiretrovirals for HIV treatment and prevention were positioned and how knowledge was mobilised to judge and discourage ‘irresponsible/incorrect’ behaviour. The complex nature of participants' accounts suggests that ‘rather than see [the participants] as moving in a context and as an effect of a context […] we might recognize the informational context as embodied in [them]’ (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 76). We suggest that participants were not only products of their engagement with HIV prevention and treatment, but this information was demonstrated through practices and knowledge that flowed through them and antiretrovirals to be harnessed in a new viral context. Our study offers insights into how GBM become ‘informed matter’ in the COVID‐19 context by articulating and working through prior and new knowledge about antiretrovirals, as well as—for most participants—their experience of consuming these drugs.</p>
<p>Findings on TDF/FTC's benefit as a therapy for COVID‐19 are mixed (Sousa et al. <a href="#shil70078-bib-0015" class="usa-link" aria-describedby="shil70078-bib-0015">2020</a>; Del Amo et al. <a href="#shil70078-bib-0011" class="usa-link" aria-describedby="shil70078-bib-0011"><sup>2022</sup></a>; Reyniers et al. <a href="#shil70078-bib-0040" class="usa-link" aria-describedby="shil70078-bib-0040"><sup>2021</sup></a>; Verburgh et al. <a href="#shil70078-bib-0053" class="usa-link" aria-describedby="shil70078-bib-0053"><sup>2023</sup></a>). Studies among people using antiretrovirals for HIV prevention or treatment investigated the effectiveness of TDF/FTC's ability to reduce transmission and prevent severe illness from COVID‐19 (Ayerdi et al. <a href="#shil70078-bib-0002" class="usa-link" aria-describedby="shil70078-bib-0002">2020</a>; Charre et al. <a href="#shil70078-bib-0009" class="usa-link" aria-describedby="shil70078-bib-0009"><sup>2020</sup></a>; Del Amo et al. <a href="#shil70078-bib-0011" class="usa-link" aria-describedby="shil70078-bib-0011"><sup>2022</sup></a>; Fernandes et al. <a href="#shil70078-bib-0019" class="usa-link" aria-describedby="shil70078-bib-0019"><sup>2020</sup></a>). Findings continue to be published on the effects of TDF/FTC among PLHIV (Verburgh et al. <a href="#shil70078-bib-0053" class="usa-link" aria-describedby="shil70078-bib-0053">2023</a>; Möller et al. <a href="#shil70078-bib-0057" class="usa-link" aria-describedby="shil70078-bib-0057"><sup>2023</sup></a>). Knowledge about the effectiveness of antiretrovirals, particularly TDF/FTC, was bound up in the ‘traffic’ of information in participants' accounts about their uses for COVID‐19. However, as we have argued, the separation of information and flesh that pervades conventional thought misses relational processes and risks simplifying biotechnologies and behaviour to relations of linear causality. Using ‘informed matter’, we can think beyond constructions of biotechnologies as creating ‘“good” or “bad” effects’ (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 5) in behaviour and interrogate ‘the relational process that biomedical interventions partake in and for which their design—involving a traffic in subject/body—can be held at least partially responsible’ (81).</p>
<p>To our knowledge, this is the first study that investigates the responses of people who use antiretrovirals when considering their use for the novel coronavirus, COVID‐19. We know that GBM in Australia are largely willing to take up new prevention methods in response to viral outbreaks, as has been shown with COVID‐19 vaccines (Holt et al. <a href="#shil70078-bib-0027" class="usa-link" aria-describedby="shil70078-bib-0027">2022</a>; Prestage et al. <a href="#shil70078-bib-0037" class="usa-link" aria-describedby="shil70078-bib-0037"><sup>2022</sup></a>). Yet, there is little investigation among this population, let alone others, into the relationships these populations have with biotechnologies beyond treatment or prevention. GBM have co‐produced TDF/FTC through their engagement with it in the context of HIV treatment and prevention, alongside pharmaceutical, virological and epidemiological information, over decades. As we have explored, some participants harnessed experiential and empirical knowledge about antiretrovirals to develop a viewpoint—and diverging viewpoints—about their appropriateness for COVID‐19 (e.g., transmission pathways, virus structure, TDF/FTC developed for a specific virus). Although mostly speculative in nature, due to the lack of evidence at the time of interviews, some participants noted that knowledge and experience with TDF/FTC was, mostly, not ‘evidence enough’ (Lancaster et al. <a href="#shil70078-bib-0032" class="usa-link" aria-describedby="shil70078-bib-0032">2020</a>) to seriously influence changes in behaviour. Lancaster et al. (<a href="#shil70078-bib-0032" class="usa-link" aria-describedby="shil70078-bib-0032">2020</a>) use the concept ‘evidence enough’ to make sense of the rapid generation and translation of health evidence to inform decisions about what is not known throughout COVID‐19. For our purposes, the phrase highlights the role that both experiential and empirical information play in constructing how GBM approach new uses of an existing biotechnology.</p>
<p>Much of this knowledge was used as a way of speculating about TDF/FTC and COVID‐19. Although there are parallels between our analysis of the recent COVID‐19 context and Rosengarten's analysis of HIV, there are some differences to note. As mentioned earlier, Rosengarten was writing at a time when knowledge was emerging about the effect of viral suppression on lowering the risk of transmission of HIV to sexual partners (especially between men). This preventative effect of viral suppression had already been discussed as a possibility for over a decade and was beginning to be accepted and adopted by authoritative bodies (see the Swiss Consensus Statement (Vernazza et al. <a href="#shil70078-bib-0054" class="usa-link" aria-describedby="shil70078-bib-0054">2008</a>)). This knowledge was well covered in the media, particularly gay community media. Practices were, therefore, not an unexpected line of inquiry.</p>
<p>In contrast, the idea that HIV antiretrovirals could prevent transmission of a different virus (SARS‐CoV‐2) or reduce the severity of the disease it caused, COVID‐19, was a more speculative proposition, even for those who were aware of findings suggesting it as a possibility (Del Amo et al. <a href="#shil70078-bib-0010" class="usa-link" aria-describedby="shil70078-bib-0010">2020</a>, <a href="#shil70078-bib-0011" class="usa-link" aria-describedby="shil70078-bib-0011">2022</a>). Additionally, crucially, the direct link with sex is not present with COVID‐19 as it is with HIV, which may explain why there has been less attention to moralistic positions about the former. However, we still argue that ‘informed matter’ has been useful to explore how participants mobilised information about HIV antiretrovirals in the context of COVID‐19.</p>
<p>Certainly, there are potentially important dimensions of understanding GBM's sense‐making about antiretrovirals as ‘informed matter’ that this analysis has not thoroughly illuminated. Firstly, our data, largely collected during lockdowns, did not yield GBM's in‐depth reflections on relations between bodies in sexual contexts. Hence, compared with Rosengarten's analysis, the importance of these relations in shaping how antiretrovirals materialise in bodies is not foregrounded in our analysis. Secondly, participants' accounts were reflective of neoliberal framings of antiretrovirals for COVID‐19, based on decisions about the self and rarely discussed antiretrovirals for COVID‐19 in relation to other people, and this warrants further investigation. Further, because in drawing on the concept of ‘informed matter’, our analysis eschews rather than describes linear causal pathways, our findings may not easily align with conventional ways of thinking about interventions, making them challenging to adopt and use to inform interventions in crises, such as COVID‐19, which demand quick actions often targeting obvious solutions. Still, attempts to challenge convention and taking the necessary time to do so should not be the reasons that analyses like ours are disregarded or delayed. In fact, we argue that grappling with what becomes normative in these or other public health emergencies is necessary. As Rosengarten suggests, analyses of ‘informed matter’ are useful when sex‐associated biomedicine is understood to produce ‘good’ or ‘bad’ behaviours, ‘for instance, the morning after pill, the vaccine against cervical [and anal] cancer, or PEP’ (<a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 13). Similar analyses could be conducted with people using doxycycline as prophylaxis for STIs, for example. Although the use of antiretrovirals as an intervention for COVID‐19 has not eventuated beyond research, by being attentive to how knowledge can produce ontological heterogeneity (Rosengarten <a href="#shil70078-bib-0041" class="usa-link" aria-describedby="shil70078-bib-0041">2009</a>, 77) in relation to other sex‐associated biotechnologies.</p></section><section id="shil70078-sec-0110"><h2 class="pmc_sec_title">5. Conclusion</h2>
<p>By using ‘informed matter’ to investigate how GBM in Australia were engaging with and employing knowledge to speculate on the potential of TDF/FTC and other antiretrovirals to prevent COVID‐19, we can look beyond binary understandings of GBM's sense‐making as simply ‘good’ or ‘bad’. Our analysis highlights the importance of investigating how heterogeneous embodied experiences with biotechnologies influence how users of these technologies make decisions about use in a new and contested informational context. Emphasising a focus on how users of biotechnologies become ‘informed matter’, we can get to relations that impact the processes between antiretrovirals (or other therapeutics) and the people who use them. In particular, when there is the potential for moralism and the oversimplification of their impact on behaviours that go on to inform responses to use. In other words, ‘informed matter’ is useful to interrogate, often neglected, complex changes in sex‐associated biotechnologies in complicated informational contexts, such as a global pandemic.</p></section><section id="shil70078-sec-0120"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>
<strong>Daniel Storer:</strong> conceptualization (lead), data curation (lead), formal analysis (lead), investigation (lead), methodology (equal), project administration (lead), writing – original draft (lead), writing – review and editing (equal). <strong>Dean Murphy:</strong> conceptualization (supporting), formal analysis (supporting), methodology (equal), supervision (equal), writing – review and editing (equal). <strong>Niamh Stephenson:</strong> conceptualization (supporting), formal analysis (supporting), supervision (equal), writing – review and editing (equal). <strong>Garrett Prestage:</strong> conceptualization (supporting), formal analysis (supporting), funding acquisition (lead), methodology (equal), supervision (equal), writing – review and editing (equal). <strong>Mohamed A. Hammoud:</strong> funding acquisition (equal), methodology (supporting), writing – review and editing (supporting).</p></section><section id="shil70078-sec-0140"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>Ethical approval was provided by the UNSW Human Research Ethics Committee.</p></section><section id="shil70078-sec-0150"><h2 class="pmc_sec_title">Consent</h2>
<p>All participants provided written consent prior to being interviewed.</p></section><section id="shil70078-sec-0160"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="shil70078-sec-0130" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We thank all participants for their generosity in sharing their experiences and their contributions to the broader Flux Study. Open access publishing facilitated by University of New South Wales, as part of the Wiley ‐ University of New South Wales agreement via the Council of Australian University Librarians.</p></section><section id="notes1"><p>


Storer, Daniel
, Murphy Dean, Stephenson Niamh, Prestage Garrett, and Hammoud Mohamed A.. 2025. “The ‘Informed Matter’ of Gay and Bisexual Men's (Potential) Use of HIV Antiretrovirals to Prevent COVID‐19.”
Sociology of Health &amp; Illness: e70078. 10.1111/1467-9566.70078.
</p>
<section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="shil70078-note-0001"><p>
<strong>Funding:</strong> This research was funded through the NSW Ministry of Health BBV and STI Research, Intervention and Strategic Evaluation Program (BRISE). DS is supported by an Australian Government Research Training Program (RTP) Scholarship.</p></div></div></section></section><section id="shil70078-ntgp-0002" class="fn-group"><h2 class="pmc_sec_title">Endnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="shil70078-note-0003">
<sup>
<sup>1</sup>
</sup><p class="display-inline">It is convention in academic writing about pharmaceuticals to use the generic name over the brand name. However, many participants refer to TDF/FTC's brand name, Truvada, produced by Gilead Sciences Inc. For this article, it is also beneficial to use the generic name to highlight that TDF/FTC is a two‐drug formulation. Each of the drugs has its own history in the treatment of HIV and other viruses, for example, tenofovir for hepatitis B.</p>
</div>
<div class="fn p" id="shil70078-note-0004">
<sup>
<sup>2</sup>
</sup><p class="display-inline">Early debate about SARS‐CoV‐2 transmission included fomites, droplets from saliva or other fluids, and aerosols. Initial health promotion focused on reducing fomites by promoting handwashing and avoiding face touching. However, evidence for droplet and aerosol transmission became more dominant as the pandemic progressed.</p>
</div>
<div class="fn p" id="shil70078-note-0005">
<sup>
<sup>3</sup>
</sup><p class="display-inline">CD4 cells are central to the immune system's response to infections and are paradoxically the targets of HIV. HIV kills the CD4 cell when replication has finished and moves on to other CD4 cells.</p>
</div>
<div class="fn p" id="shil70078-note-0006">
<sup>
<sup>4</sup>
</sup><p class="display-inline">In Australian jurisdictions, the chief health officers reached quasi‐celebrity status through their daily presence in COVID‐19 press conferences outlining case numbers, outbreaks, deaths and changes to restrictions on movement throughout 2020 to 2022.</p>
</div>
</div></section><section id="shil70078-sec-0180"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>Research data are not shared.</p></section><section id="shil70078-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="shil70078-bibl-0001_sec2"><ol class="ref-list font-sm">
<li id="shil70078-bib-0001">
<cite>
ASHM
. 2023. Post‐Exposure Prophylaxis After Non‐Occupational and Occupational Exposure to HIV: Australian National Guidelines. 3rd ed. ASHM. <a href="https://pep.guidelines.org.au/guidelines/prescribing-pep/recommended-pep-regimens/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://pep.guidelines.org.au/guidelines/prescribing‐pep/recommended‐pep‐regimens/</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Post%E2%80%90Exposure%20Prophylaxis%20After%20Non%E2%80%90Occupational%20and%20Occupational%20Exposure%20to%20HIV:%20Australian%20National%20Guidelines&amp;publication_year=2023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0002">
<cite>

Ayerdi, O.
, Puerta T., Clavo P., et al. 2020. “Preventive Efficacy of Tenofovir/emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre‐Exposure Prophylaxis Users.” Open Forum Infectious Diseases
7, no. 11: ofaa455. 10.1093/ofid/ofaa455.
</cite> [<a href="https://doi.org/10.1093/ofid/ofaa455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7543639/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33200081/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Open%20Forum%20Infectious%20Diseases&amp;title=Preventive%20Efficacy%20of%20Tenofovir/emtricitabine%20Against%20Severe%20Acute%20Respiratory%20Syndrome%20Coronavirus%202%20Among%20Pre%E2%80%90Exposure%20Prophylaxis%20Users&amp;author=O.%20Ayerdi&amp;author=T.%20Puerta&amp;author=P.%20Clavo&amp;volume=7&amp;issue=11&amp;publication_year=2020&amp;pages=ofaa455&amp;pmid=33200081&amp;doi=10.1093/ofid/ofaa455&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0003">
<cite>

Barry, A.

2005. “Pharmaceutical Matters: The Invention of Informed Materials.” Theory, Culture &amp; Society
22, no. 1: 51–69. 10.1177/0263276405048433.</cite> [<a href="https://doi.org/10.1177/0263276405048433" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theory,%20Culture%20&amp;%20Society&amp;title=Pharmaceutical%20Matters:%20The%20Invention%20of%20Informed%20Materials&amp;author=A.%20Barry&amp;volume=22&amp;issue=1&amp;publication_year=2005&amp;pages=51-69&amp;doi=10.1177/0263276405048433&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0004">
<cite>

Beekmann, S. E.
, and Henderson D. K.. 2014. “Prevention of Human Immunodeficiency Virus and AIDS: Postexposure Prophylaxis (Including Health Care Workers).” Infectious Disease Clinics of North America
28, no. 4: 601–613. 10.1016/j.idc.2014.08.005.
</cite> [<a href="https://doi.org/10.1016/j.idc.2014.08.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4253549/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25287589/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Infectious%20Disease%20Clinics%20of%20North%20America&amp;title=Prevention%20of%20Human%20Immunodeficiency%20Virus%20and%20AIDS:%20Postexposure%20Prophylaxis%20(Including%20Health%20Care%20Workers)&amp;author=S.%20E.%20Beekmann&amp;author=D.%20K.%20Henderson&amp;volume=28&amp;issue=4&amp;publication_year=2014&amp;pages=601-613&amp;pmid=25287589&amp;doi=10.1016/j.idc.2014.08.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0005">
<cite>

Braun, V.
, and Clarke V.. 2019. “Reflecting on Reflexive Thematic Analysis.” Qualitative Research in Sport, Exercise and Health
11, no. 4: 589–597. 10.1080/2159676x.2019.1628806.</cite> [<a href="https://doi.org/10.1080/2159676x.2019.1628806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Qualitative%20Research%20in%20Sport,%20Exercise%20and%20Health&amp;title=Reflecting%20on%20Reflexive%20Thematic%20Analysis&amp;author=V.%20Braun&amp;author=V.%20Clarke&amp;volume=11&amp;issue=4&amp;publication_year=2019&amp;pages=589-597&amp;doi=10.1080/2159676x.2019.1628806&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0006">
<cite>

Broady, T.
, Rance J., Cama E., et al. 2024. Annual Report of Trends in Behaviour 2024: Viral Hepatitis, HIV, STIs and Sexual Health in Australia. Centre for Social Research in Health, UNSW Sydney.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Annual%20Report%20of%20Trends%20in%20Behaviour%202024:%20Viral%20Hepatitis,%20HIV,%20STIs%20and%20Sexual%20Health%20in%20Australia&amp;author=T.%20Broady&amp;author=J.%20Rance&amp;author=E.%20Cama&amp;publication_year=2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0007">
<cite>

Brown, G.
, and Di Feliciantonio C.. 2022. “Geographies of PrEP, TasP and Undetectability: Reconceptualising HIV Assemblages to Explore What Else Matters in the Lives of Gay and Bisexual Men.” Dialogues in Human Geography
12, no. 1: 100–118. 10.1177/2043820621989574.</cite> [<a href="https://doi.org/10.1177/2043820621989574" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dialogues%20in%20Human%20Geography&amp;title=Geographies%20of%20PrEP,%20TasP%20and%20Undetectability:%20Reconceptualising%20HIV%20Assemblages%20to%20Explore%20What%20Else%20Matters%20in%20the%20Lives%20of%20Gay%20and%20Bisexual%20Men&amp;author=G.%20Brown&amp;author=C.%20Di%20Feliciantonio&amp;volume=12&amp;issue=1&amp;publication_year=2022&amp;pages=100-118&amp;doi=10.1177/2043820621989574&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0008">
<cite>

Cao, B.
, Wang Y., Wen D., et al. 2020. “A Trial of Lopinavir–Ritonavir in Adults Hospitalized With Severe Covid‐19.” New England Journal of Medicine
382, no. 19: 1787–1799. 10.1056/NEJMoa2001282.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2001282" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7121492/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32187464/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=A%20Trial%20of%20Lopinavir%E2%80%93Ritonavir%20in%20Adults%20Hospitalized%20With%20Severe%20Covid%E2%80%9019&amp;author=B.%20Cao&amp;author=Y.%20Wang&amp;author=D.%20Wen&amp;volume=382&amp;issue=19&amp;publication_year=2020&amp;pages=1787-1799&amp;pmid=32187464&amp;doi=10.1056/NEJMoa2001282&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0009">
<cite>

Charre, C.
, Icard V., Pradat P., et al. 2020. “Coronavirus Disease 2019 Attack Rate in HIV‐Infected Patients and in Preexposure Prophylaxis Users.” AIDS
34, no. 12: 1765–1770. 10.1097/QAD.0000000000002639.
</cite> [<a href="https://doi.org/10.1097/QAD.0000000000002639" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7493781/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32889852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Coronavirus%20Disease%202019%20Attack%20Rate%20in%20HIV%E2%80%90Infected%20Patients%20and%20in%20Preexposure%20Prophylaxis%20Users&amp;author=C.%20Charre&amp;author=V.%20Icard&amp;author=P.%20Pradat&amp;volume=34&amp;issue=12&amp;publication_year=2020&amp;pages=1765-1770&amp;pmid=32889852&amp;doi=10.1097/QAD.0000000000002639&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0014">
<cite>

de Sousa, A. F. L.
, de Oliveira L. B., Queiroz A., et al. 2021. “Casual Sex Among Men Who Have Sex With Men (MSM) During the Period of Sheltering in Place to Prevent the Spread of COVID‐19.” International Journal of Environmental Research and Public Health
18, no. 6: 3266. 10.3390/ijerph18063266.
</cite> [<a href="https://doi.org/10.3390/ijerph18063266" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8004123/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33809916/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Environmental%20Research%20and%20Public%20Health&amp;title=Casual%20Sex%20Among%20Men%20Who%20Have%20Sex%20With%20Men%20(MSM)%20During%20the%20Period%20of%20Sheltering%20in%20Place%20to%20Prevent%20the%20Spread%20of%20COVID%E2%80%9019&amp;author=A.%20F.%20L.%20de%20Sousa&amp;author=L.%20B.%20de%20Oliveira&amp;author=A.%20Queiroz&amp;volume=18&amp;issue=6&amp;publication_year=2021&amp;pages=3266&amp;pmid=33809916&amp;doi=10.3390/ijerph18063266&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0010">
<cite>

Del Amo, J.
, Polo R., Moreno S., et al. 2020. “Incidence and Severity of COVID‐19 in HIV‐Positive Persons Receiving Antiretroviral Therapy: A Cohort Study.” Annals of Internal Medicine
173, no. 7: 536–541. 10.7326/M20-3689.
</cite> [<a href="https://doi.org/10.7326/M20-3689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7394316/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32589451/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Internal%20Medicine&amp;title=Incidence%20and%20Severity%20of%20COVID%E2%80%9019%20in%20HIV%E2%80%90Positive%20Persons%20Receiving%20Antiretroviral%20Therapy:%20A%20Cohort%20Study&amp;author=J.%20Del%20Amo&amp;author=R.%20Polo&amp;author=S.%20Moreno&amp;volume=173&amp;issue=7&amp;publication_year=2020&amp;pages=536-541&amp;pmid=32589451&amp;doi=10.7326/M20-3689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0011">
<cite>

Del Amo, J.
, Polo R., Moreno S., et al. 2022. “Tenofovir Disoproxil Fumarate/Emtricitabine and Severity of Coronavirus Disease 2019 in People With HIV Infection.” AIDS
36, no. 15: 2171–2179. 10.1097/QAD.0000000000003372.
</cite> [<a href="https://doi.org/10.1097/QAD.0000000000003372" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9673178/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36382436/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Tenofovir%20Disoproxil%20Fumarate/Emtricitabine%20and%20Severity%20of%20Coronavirus%20Disease%202019%20in%20People%20With%20HIV%20Infection&amp;author=J.%20Del%20Amo&amp;author=R.%20Polo&amp;author=S.%20Moreno&amp;volume=36&amp;issue=15&amp;publication_year=2022&amp;pages=2171-2179&amp;pmid=36382436&amp;doi=10.1097/QAD.0000000000003372&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0012">
<cite>

Delaugerre, C.
, Assoumou L., Maylin S., et al. 2022. “Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV‐Negative Participants Using Tenofovir/Emtricitabine‐Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS‐Sero Cohorts.” Open Forum Infectious Diseases
9, no. 7: ofac188. 10.1093/ofid/ofac188.
</cite> [<a href="https://doi.org/10.1093/ofid/ofac188" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9047207/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35791355/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Open%20Forum%20Infectious%20Diseases&amp;title=Severe%20Acute%20Respiratory%20Syndrome%20Coronavirus%202%20Seroprevalence%20Among%20HIV%E2%80%90Negative%20Participants%20Using%20Tenofovir/Emtricitabine%E2%80%90Based%20Preexposure%20Prophylaxis%20in%202020:%20A%20Substudy%20of%20the%20French%20National%20Agency%20for%20Research%20on%20AIDS%20and%20Viral%20Hepatitis%20PREVENIR%20and%20Inserm%20SAPRIS%E2%80%90Sero%20Cohorts&amp;author=C.%20Delaugerre&amp;author=L.%20Assoumou&amp;author=S.%20Maylin&amp;volume=9&amp;issue=7&amp;publication_year=2022&amp;pages=ofac188&amp;pmid=35791355&amp;doi=10.1093/ofid/ofac188&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0013">
<cite>

Deleuze, G.
, and Guattari F. l.. 1988. 
A Thousand Plateaus: Capitalism and Schizophrenia
. Translated by B. Massumi Continuum.</cite> [<a href="https://scholar.google.com/scholar_lookup?Deleuze,%20G.%20,%20and%20Guattari%20F.%20l..%201988.%20A%20Thousand%20Plateaus:%20Capitalism%20and%20Schizophrenia%20.%20Translated%20by%20B.%20Massumi%20Continuum." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0016">
<cite>

Di Perri, G.

2021. “Tenofovir Alafenamide (TAF) Clinical Pharmacology.” La Infezioni in Medicina
29, no. 4: 526–529. 10.53854/liim-2904-4.</cite> [<a href="https://doi.org/10.53854/liim-2904-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8805468/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35146360/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=La%20Infezioni%20in%20Medicina&amp;title=Tenofovir%20Alafenamide%20(TAF)%20Clinical%20Pharmacology&amp;author=G.%20Di%20Perri&amp;volume=29&amp;issue=4&amp;publication_year=2021&amp;pages=526-529&amp;pmid=35146360&amp;doi=10.53854/liim-2904-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0017">
<cite>

Eastman, R. T.
, Roth J. S., Brimacombe K. R., et al. 2020. “Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID‐19.” ACS Central Science
6, no. 5: 672–683. 10.1021/acscentsci.0c00489.
</cite> [<a href="https://doi.org/10.1021/acscentsci.0c00489" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7202249/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32483554/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ACS%20Central%20Science&amp;title=Remdesivir:%20A%20Review%20of%20Its%20Discovery%20and%20Development%20Leading%20to%20Emergency%20Use%20Authorization%20for%20Treatment%20of%20COVID%E2%80%9019&amp;author=R.%20T.%20Eastman&amp;author=J.%20S.%20Roth&amp;author=K.%20R.%20Brimacombe&amp;volume=6&amp;issue=5&amp;publication_year=2020&amp;pages=672-683&amp;pmid=32483554&amp;doi=10.1021/acscentsci.0c00489&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0018">
<cite>
European Medicines Agency
. 2023. Truvada. European Medicines Agency. <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/truvada#ema-inpage-item-authorisation-details" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/medicines/human/EPAR/truvada#ema‐inpage‐item‐authorisation‐details</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?European%20Medicines%20Agency%20.%202023.%20Truvada.%20European%20Medicines%20Agency.%20https://www.ema.europa.eu/en/medicines/human/EPAR/truvada#ema%E2%80%90inpage%E2%80%90item%E2%80%90authorisation%E2%80%90details." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0019">
<cite>

Fernandes, D. E.
, Ferreira P. R. A., and Mastroianni Kirsztajn G.. 2020. “Pre‐exposure Prophylaxis During the SARS‐CoV‐2 Pandemic: Can PrEP Prevent COVID‐19‐Related Symptoms?” Epidemiology and Infection
148: e231. 10.1017/S0950268820002253.
</cite> [<a href="https://doi.org/10.1017/S0950268820002253" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7556904/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32981567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Epidemiology%20and%20Infection&amp;title=Pre%E2%80%90exposure%20Prophylaxis%20During%20the%20SARS%E2%80%90CoV%E2%80%902%20Pandemic:%20Can%20PrEP%20Prevent%20COVID%E2%80%9019%E2%80%90Related%20Symptoms?&amp;author=D.%20E.%20Fernandes&amp;author=P.%20R.%20A.%20Ferreira&amp;author=G.%20Mastroianni%20Kirsztajn&amp;volume=148&amp;publication_year=2020&amp;pages=e231&amp;pmid=32981567&amp;doi=10.1017/S0950268820002253&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0020">
<cite>

Gagnon, M.
, and Holmes D.. 2016. “Body–Drug Assemblages: Theorizing the Experience of Side Effects in the Context of HIV Treatment.” Nursing Philosophy
17, no. 4: 250–261. 10.1111/nup.12136.
</cite> [<a href="https://doi.org/10.1111/nup.12136" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5035547/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27435229/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nursing%20Philosophy&amp;title=Body%E2%80%93Drug%20Assemblages:%20Theorizing%20the%20Experience%20of%20Side%20Effects%20in%20the%20Context%20of%20HIV%20Treatment&amp;author=M.%20Gagnon&amp;author=D.%20Holmes&amp;volume=17&amp;issue=4&amp;publication_year=2016&amp;pages=250-261&amp;pmid=27435229&amp;doi=10.1111/nup.12136&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0021">
<cite>
Gilead
. 2008. U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults. Gilead. <a href="https://www.gilead.com/news/news-details/2008/us-food-and-drug-administration-approves-vireadr-for-chronic-hepatitis-b-in-adults" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.gilead.com/news/news‐details/2008/us‐food‐and‐drug‐administration‐approves‐vireadr‐for‐chronic‐hepatitis‐b‐in‐adults</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?Gilead%20.%202008.%20U.S.%20Food%20and%20Drug%20Administration%20Approves%20Viread(R)%20for%20Chronic%20Hepatitis%20B%20in%20Adults.%20Gilead.%20https://www.gilead.com/news/news%E2%80%90details/2008/us%E2%80%90food%E2%80%90and%E2%80%90drug%E2%80%90administration%E2%80%90approves%E2%80%90vireadr%E2%80%90for%E2%80%90chronic%E2%80%90hepatitis%E2%80%90b%E2%80%90in%E2%80%90adults." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0022">
<cite>

Grant, R. M.
, Lama J. R., Anderson P. L., et al. 2010. “Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex With Men.” New England Journal of Medicine
363, no. 27: 2587–2599. 10.1056/NEJMoa1011205.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1011205" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3079639/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21091279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Preexposure%20Chemoprophylaxis%20for%20HIV%20Prevention%20in%20Men%20Who%20Have%20Sex%20With%20Men&amp;author=R.%20M.%20Grant&amp;author=J.%20R.%20Lama&amp;author=P.%20L.%20Anderson&amp;volume=363&amp;issue=27&amp;publication_year=2010&amp;pages=2587-2599&amp;pmid=21091279&amp;doi=10.1056/NEJMoa1011205&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0023">
<cite>

Hakim, J.
, Young I., and Cummings J.. 2022. “Sex in the Time of Coronavirus: Queer Men Negotiating Biosexual Citizenship During the COVID‐19 Pandemic.” Continuum
36, no. 2: 289–301. 10.1080/10304312.2021.1992350.</cite> [<a href="https://doi.org/10.1080/10304312.2021.1992350" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Continuum&amp;title=Sex%20in%20the%20Time%20of%20Coronavirus:%20Queer%20Men%20Negotiating%20Biosexual%20Citizenship%20During%20the%20COVID%E2%80%9019%20Pandemic&amp;author=J.%20Hakim&amp;author=I.%20Young&amp;author=J.%20Cummings&amp;volume=36&amp;issue=2&amp;publication_year=2022&amp;pages=289-301&amp;doi=10.1080/10304312.2021.1992350&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0024">
<cite>

Hammoud, M. A.
, Maher L., Holt M., et al. 2020. “Physical Distancing Due To COVID‐19 Disrupts Sexual Behaviors Among Gay and Bisexual Men in Australia: Implications for Trends in HIV and Other Sexually Transmissible Infections.” Journal of Acquired Immune Deficiency Syndromes
85, no. 3: 309–315. 10.1097/QAI.0000000000002462.
</cite> [<a href="https://doi.org/10.1097/QAI.0000000000002462" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32740374/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Acquired%20Immune%20Deficiency%20Syndromes&amp;title=Physical%20Distancing%20Due%20To%20COVID%E2%80%9019%20Disrupts%20Sexual%20Behaviors%20Among%20Gay%20and%20Bisexual%20Men%20in%20Australia:%20Implications%20for%20Trends%20in%20HIV%20and%20Other%20Sexually%20Transmissible%20Infections&amp;author=M.%20A.%20Hammoud&amp;author=L.%20Maher&amp;author=M.%20Holt&amp;volume=85&amp;issue=3&amp;publication_year=2020&amp;pages=309-315&amp;pmid=32740374&amp;doi=10.1097/QAI.0000000000002462&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0025">
<cite>

Holt, M.

2013. “Enacting and Imagining Gay Men: The Looping Effects of Behavioural HIV Surveillance in Australia.” Critical Public Health
23, no. 4: 404–417. 10.1080/09581596.2013.796038.</cite> [<a href="https://doi.org/10.1080/09581596.2013.796038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Critical%20Public%20Health&amp;title=Enacting%20and%20Imagining%20Gay%20Men:%20The%20Looping%20Effects%20of%20Behavioural%20HIV%20Surveillance%20in%20Australia&amp;author=M.%20Holt&amp;volume=23&amp;issue=4&amp;publication_year=2013&amp;pages=404-417&amp;doi=10.1080/09581596.2013.796038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0026">
<cite>

Holt, M.

2015. “Configuring the Users of New HIV‐Prevention Technologies: The Case of HIV Pre‐Exposure Prophylaxis.” Culture, Health and Sexuality
17, no. 4: 428–439. 10.1080/13691058.2014.960003.</cite> [<a href="https://doi.org/10.1080/13691058.2014.960003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25270549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Culture,%20Health%20and%20Sexuality&amp;title=Configuring%20the%20Users%20of%20New%20HIV%E2%80%90Prevention%20Technologies:%20The%20Case%20of%20HIV%20Pre%E2%80%90Exposure%20Prophylaxis&amp;author=M.%20Holt&amp;volume=17&amp;issue=4&amp;publication_year=2015&amp;pages=428-439&amp;pmid=25270549&amp;doi=10.1080/13691058.2014.960003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0027">
<cite>

Holt, M.
, MacGibbon J., Bavinton B., et al. 2022. “COVID‐19 Vaccination Uptake and Hesitancy in a National Sample of Australian Gay and Bisexual Men.” AIDS and Behavior
26, no. 8: 2531–2538. 10.1007/s10461-022-03603-x.
</cite> [<a href="https://doi.org/10.1007/s10461-022-03603-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8803280/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35102499/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS%20and%20Behavior&amp;title=COVID%E2%80%9019%20Vaccination%20Uptake%20and%20Hesitancy%20in%20a%20National%20Sample%20of%20Australian%20Gay%20and%20Bisexual%20Men&amp;author=M.%20Holt&amp;author=J.%20MacGibbon&amp;author=B.%20Bavinton&amp;volume=26&amp;issue=8&amp;publication_year=2022&amp;pages=2531-2538&amp;pmid=35102499&amp;doi=10.1007/s10461-022-03603-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0028">
<cite>

Johnson, C.

2020a. PrEP Manufacturer to Test Drug Against COVID‐19—But Has Low Expectations. Washington Blade. <a href="https://www.washingtonblade.com/2020/03/27/prep-manufacturer-to-test-drug-against-covid-19-but-has-low-expectations/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.washingtonblade.com/2020/03/27/prep‐manufacturer‐to‐test‐drug‐against‐covid‐19‐but‐has‐low‐expectations/</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=PrEP%20Manufacturer%20to%20Test%20Drug%20Against%20COVID%E2%80%9019%E2%80%94But%20Has%20Low%20Expectations&amp;author=C.%20Johnson&amp;publication_year=2020a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0029">
<cite>

Johnson, C.

2020b. PrEP May Be Tested Against Coronavirus if Antivirals Shown to Work. Washington Blade. <a href="https://www.washingtonblade.com/2020/03/24/prep-may-be-tested-against-coronavirus-if-hiv-meds-shown-to-work/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.washingtonblade.com/2020/03/24/prep‐may‐be‐tested‐against‐coronavirus‐if‐hiv‐meds‐shown‐to‐work/</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=PrEP%20May%20Be%20Tested%20Against%20Coronavirus%20if%20Antivirals%20Shown%20to%20Work&amp;author=C.%20Johnson&amp;publication_year=2020b&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0030">
<cite>

Kellerman, S. E.
, Hutchinson A. B., Begley E. B., Boyett B. C., Clark H. A., and Sullivan P.. 2006. “Knowledge and Use of HIV Pre‐Exposure Prophylaxis Among Attendees of Minority Gay Pride Events, 2004.” Journal of Acuired Immune Deficiency Syndromes
43, no. 3: 376–377. 10.1097/01.qai.0000234085.18914.d5.</cite> [<a href="https://doi.org/10.1097/01.qai.0000234085.18914.d5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17079995/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Acuired%20Immune%20Deficiency%20Syndromes&amp;title=Knowledge%20and%20Use%20of%20HIV%20Pre%E2%80%90Exposure%20Prophylaxis%20Among%20Attendees%20of%20Minority%20Gay%20Pride%20Events,%202004&amp;author=S.%20E.%20Kellerman&amp;author=A.%20B.%20Hutchinson&amp;author=E.%20B.%20Begley&amp;author=B.%20C.%20Boyett&amp;author=H.%20A.%20Clark&amp;volume=43&amp;issue=3&amp;publication_year=2006&amp;pages=376-377&amp;pmid=17079995&amp;doi=10.1097/01.qai.0000234085.18914.d5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0031">
<cite>

Krakower, D. S.
, Mimiaga M. J., Rosenberger J. G., et al. 2012. “Limited Awareness and Low Immediate Uptake of Pre‐Exposure Prophylaxis Among Men Who Have Sex With Men Using an Internet Social Networking Site.” PLoS One
7, no. 3: e33119. 10.1371/journal.pone.0033119.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0033119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3314648/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22470438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Limited%20Awareness%20and%20Low%20Immediate%20Uptake%20of%20Pre%E2%80%90Exposure%20Prophylaxis%20Among%20Men%20Who%20Have%20Sex%20With%20Men%20Using%20an%20Internet%20Social%20Networking%20Site&amp;author=D.%20S.%20Krakower&amp;author=M.%20J.%20Mimiaga&amp;author=J.%20G.%20Rosenberger&amp;volume=7&amp;issue=3&amp;publication_year=2012&amp;pages=e33119&amp;pmid=22470438&amp;doi=10.1371/journal.pone.0033119&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0032">
<cite>

Lancaster, K.
, Rhodes T., and Rosengarten M.. 2020. “Making Evidence and Policy in Public Health Emergencies: Lessons From COVID‐19 for Adaptive Evidence‐Making and Intervention.” Evidence &amp; Policy
16, no. 3: 477–490. 10.1332/174426420X15913559981103.</cite> [<a href="https://doi.org/10.1332/174426420X15913559981103" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Evidence%20&amp;%20Policy&amp;title=Making%20Evidence%20and%20Policy%20in%20Public%20Health%20Emergencies:%20Lessons%20From%20COVID%E2%80%9019%20for%20Adaptive%20Evidence%E2%80%90Making%20and%20Intervention&amp;author=K.%20Lancaster&amp;author=T.%20Rhodes&amp;author=M.%20Rosengarten&amp;volume=16&amp;issue=3&amp;publication_year=2020&amp;pages=477-490&amp;doi=10.1332/174426420X15913559981103&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0057">
<cite>

Möller, I. K.
, Gisslén M., Wagner P., Sparén P., and Carlander C.. 2023. “COVID‐19 Hospitalization Outcomes in Adults by HIV Status; a Nation‐Wide Register‐Based Study.” HIV Medicine
24, no. 10: 1045–1055. 10.1111/hiv.13515.
</cite> [<a href="https://doi.org/10.1111/hiv.13515" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37286199/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=HIV%20Medicine&amp;title=COVID%E2%80%9019%20Hospitalization%20Outcomes%20in%20Adults%20by%20HIV%20Status;%20a%20Nation%E2%80%90Wide%20Register%E2%80%90Based%20Study&amp;author=I.%20K.%20M%C3%B6ller&amp;author=M.%20Gissl%C3%A9n&amp;author=P.%20Wagner&amp;author=P.%20Spar%C3%A9n&amp;author=C.%20Carlander&amp;volume=24&amp;issue=10&amp;publication_year=2023&amp;pages=1045-1055&amp;pmid=37286199&amp;doi=10.1111/hiv.13515&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0034">
<cite>

Murphy, D. A.
, Race K., Pienaar K., and Lea T.. 2024. “Remaking Chemsex Event Networks in the Age of HIV Pre‐Exposure Prophylaxis (PrEP).” Body &amp; Society. 1357034X241298173. 10.1177/1357034x241298173.</cite> [<a href="https://doi.org/10.1177/1357034x241298173" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Body%20&amp;%20Society&amp;title=Remaking%20Chemsex%20Event%20Networks%20in%20the%20Age%20of%20HIV%20Pre%E2%80%90Exposure%20Prophylaxis%20(PrEP)&amp;author=D.%20A.%20Murphy&amp;author=K.%20Race&amp;author=K.%20Pienaar&amp;author=T.%20Lea&amp;publication_year=2024&amp;pages=1357034X241298173&amp;doi=10.1177/1357034x241298173&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0035">
<cite>

Panlilio, A. L.
, Cardo D. M., Grohskopf L. A., Heneine W., Ross C. S., and U.S. Public Health Service
. 2005. “Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis.” Morbidity and Mortality Weekly Report Recommendations and Reports
54, no. RR‐9: 1–17. <a href="https://stacks.cdc.gov/view/cdc/6646" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://stacks.cdc.gov/view/cdc/6646</a>.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/16195697/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Morbidity%20and%20Mortality%20Weekly%20Report%20Recommendations%20and%20Reports&amp;title=Updated%20U.S.%20Public%20Health%20Service%20Guidelines%20for%20the%20Management%20of%20Occupational%20Exposures%20to%20HIV%20and%20Recommendations%20for%20Postexposure%20Prophylaxis&amp;author=A.%20L.%20Panlilio&amp;author=D.%20M.%20Cardo&amp;author=L.%20A.%20Grohskopf&amp;author=W.%20Heneine&amp;author=C.%20S.%20Ross&amp;volume=54&amp;issue=RR%E2%80%909&amp;publication_year=2005&amp;pages=1-17&amp;pmid=16195697&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0036">
<cite>
PBS
. 2009. Tenofovir Disoproxil Fumarate, Tablet 300 Mg, Viread®, November 2008. Department of Health, Disability and Ageing. <a href="https://m.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2008-11/pbac-psd-tenofovir-nov08.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://m.pbs.gov.au/industry/listing/elements/pbac‐meetings/psd/2008‐11/pbac‐psd‐tenofovir‐nov08.html</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?PBS%20.%202009.%20Tenofovir%20Disoproxil%20Fumarate,%20Tablet%20300%20Mg,%20Viread%C2%AE,%20November%202008.%20Department%20of%20Health,%20Disability%20and%20Ageing.%20https://m.pbs.gov.au/industry/listing/elements/pbac%E2%80%90meetings/psd/2008%E2%80%9011/pbac%E2%80%90psd%E2%80%90tenofovir%E2%80%90nov08.html." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0037">
<cite>

Prestage, G.
, Storer D., Jin F., et al. 2022. “COVID‐19 Vaccine Uptake and Its Impacts in a Cohort of Gay and Bisexual Men in Australia.” AIDS and Behavior
26, no. 8: 2692–2702. 10.1007/s10461-022-03611-x.
</cite> [<a href="https://doi.org/10.1007/s10461-022-03611-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8821860/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35132480/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS%20and%20Behavior&amp;title=COVID%E2%80%9019%20Vaccine%20Uptake%20and%20Its%20Impacts%20in%20a%20Cohort%20of%20Gay%20and%20Bisexual%20Men%20in%20Australia&amp;author=G.%20Prestage&amp;author=D.%20Storer&amp;author=F.%20Jin&amp;volume=26&amp;issue=8&amp;publication_year=2022&amp;pages=2692-2702&amp;pmid=35132480&amp;doi=10.1007/s10461-022-03611-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0038">
<cite>

Race, K.

2015. “‘Party and Play’: Online Hook‐Up Devices and the Emergence of PNP Practices Among Gay Men.” Sexualities
18, no. 3: 253–275. 10.1177/1363460714550913.</cite> [<a href="https://doi.org/10.1177/1363460714550913" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sexualities&amp;title=%E2%80%98Party%20and%20Play%E2%80%99:%20Online%20Hook%E2%80%90Up%20Devices%20and%20the%20Emergence%20of%20PNP%20Practices%20Among%20Gay%20Men&amp;author=K.%20Race&amp;volume=18&amp;issue=3&amp;publication_year=2015&amp;pages=253-275&amp;doi=10.1177/1363460714550913&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0040">
<cite>

Reyniers, T.
, Rotsaert A., Thunissen E., et al. 2021. “Reduced Sexual Contacts With Non‐Steady Partners and Less PrEP Use Among MSM in Belgium During the First Weeks of the COVID‐19 Lockdown: Results of an Online Survey.” Sexually Transmitted Infections
97, no. 6: 414–419. 10.1136/sextrans-2020-054756.
</cite> [<a href="https://doi.org/10.1136/sextrans-2020-054756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7656903/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33172917/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sexually%20Transmitted%20Infections&amp;title=Reduced%20Sexual%20Contacts%20With%20Non%E2%80%90Steady%20Partners%20and%20Less%20PrEP%20Use%20Among%20MSM%20in%20Belgium%20During%20the%20First%20Weeks%20of%20the%20COVID%E2%80%9019%20Lockdown:%20Results%20of%20an%20Online%20Survey&amp;author=T.%20Reyniers&amp;author=A.%20Rotsaert&amp;author=E.%20Thunissen&amp;volume=97&amp;issue=6&amp;publication_year=2021&amp;pages=414-419&amp;pmid=33172917&amp;doi=10.1136/sextrans-2020-054756&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0041">
<cite>

Rosengarten, M.

2009. HIV Interventions: Biomedicine and the Traffic Between Information and Flesh. University of Washington Press. <a href="http://www.jstor.org/stable/j.ctvcwn8cn" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.jstor.org/stable/j.ctvcwn8cn</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=HIV%20Interventions:%20Biomedicine%20and%20the%20Traffic%20Between%20Information%20and%20Flesh&amp;author=M.%20Rosengarten&amp;publication_year=2009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0042">
<cite>

Rosengarten, M.
, and Michael M.. 2009a. “The Performative Function of Expectations in Translating Treatment to Prevention: The Case of HIV Pre‐Exposure Prophylaxis, or PrEP.” Social Science &amp; Medicine
69, no. 7: 1049–1055. 10.1016/j.socscimed.2009.07.039.
</cite> [<a href="https://doi.org/10.1016/j.socscimed.2009.07.039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19695756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Social%20Science%20&amp;%20Medicine&amp;title=The%20Performative%20Function%20of%20Expectations%20in%20Translating%20Treatment%20to%20Prevention:%20The%20Case%20of%20HIV%20Pre%E2%80%90Exposure%20Prophylaxis,%20or%20PrEP&amp;author=M.%20Rosengarten&amp;author=M.%20Michael&amp;volume=69&amp;issue=7&amp;publication_year=2009a&amp;pages=1049-1055&amp;pmid=19695756&amp;doi=10.1016/j.socscimed.2009.07.039&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0043">
<cite>

Rosengarten, M.
, and Michael M.. 2009b. “Rethinking the Bioethical Enactment of Medically Drugged Bodies: Paradoxes of Using Anti‐HIV Drug Therapy as a Technology for Prevention.” Science as Culture
18, no. 2: 183–199. 10.1080/09505430902885565.</cite> [<a href="https://doi.org/10.1080/09505430902885565" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science%20as%20Culture&amp;title=Rethinking%20the%20Bioethical%20Enactment%20of%20Medically%20Drugged%20Bodies:%20Paradoxes%20of%20Using%20Anti%E2%80%90HIV%20Drug%20Therapy%20as%20a%20Technology%20for%20Prevention&amp;author=M.%20Rosengarten&amp;author=M.%20Michael&amp;volume=18&amp;issue=2&amp;publication_year=2009b&amp;pages=183-199&amp;doi=10.1080/09505430902885565&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0045">
<cite>

Smith, A. K. J.
, Newman C. E., Haire B., and Holt M.. 2022. “Prescribing as Affective Clinical Practice: Transformations in Sexual Health Consultations Through HIV Pre‐Exposure Prophylaxis.” Sociology of Health &amp; Illness
44, no. 7: 1182–1200. 10.1111/1467-9566.13502.
</cite> [<a href="https://doi.org/10.1111/1467-9566.13502" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9546439/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35635513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sociology%20of%20Health%20&amp;%20Illness&amp;title=Prescribing%20as%20Affective%20Clinical%20Practice:%20Transformations%20in%20Sexual%20Health%20Consultations%20Through%20HIV%20Pre%E2%80%90Exposure%20Prophylaxis&amp;author=A.%20K.%20J.%20Smith&amp;author=C.%20E.%20Newman&amp;author=B.%20Haire&amp;author=M.%20Holt&amp;volume=44&amp;issue=7&amp;publication_year=2022&amp;pages=1182-1200&amp;pmid=35635513&amp;doi=10.1111/1467-9566.13502&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0044">
<cite>

Smith, A. K. J.
, Lancaster K., Rhodes T., and Holt M.. 2023. “Dosing Practices Made Mundane: Enacting HIV Pre‐Exposure Prophylaxis Adherence in Domestic Routines.” Sociology of Health &amp; Illness
45, no. 8: 1747–1764. 10.1111/1467-9566.13687.
</cite> [<a href="https://doi.org/10.1111/1467-9566.13687" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37309108/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sociology%20of%20Health%20&amp;%20Illness&amp;title=Dosing%20Practices%20Made%20Mundane:%20Enacting%20HIV%20Pre%E2%80%90Exposure%20Prophylaxis%20Adherence%20in%20Domestic%20Routines&amp;author=A.%20K.%20J.%20Smith&amp;author=K.%20Lancaster&amp;author=T.%20Rhodes&amp;author=M.%20Holt&amp;volume=45&amp;issue=8&amp;publication_year=2023&amp;pages=1747-1764&amp;pmid=37309108&amp;doi=10.1111/1467-9566.13687&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0015">
<cite>

Sousa, Á. F. L.
, Queiroz A. A. F. L. N., Lima S. V. M. A., et al. 2020. “Chemsex Practice Among Men Who Have Sex With Men (MSM) During Social Isolation From COVID‐19: Multicentric Online Survey.” Cadernos de Saúde Pública
36, no. 12: e00202420. 10.1590/0102-311X00202420.
</cite> [<a href="https://doi.org/10.1590/0102-311X00202420" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33237252/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cadernos%20de%20Sa%C3%BAde%20P%C3%BAblica&amp;title=Chemsex%20Practice%20Among%20Men%20Who%20Have%20Sex%20With%20Men%20(MSM)%20During%20Social%20Isolation%20From%20COVID%E2%80%9019:%20Multicentric%20Online%20Survey&amp;author=%C3%81.%20F.%20L.%20Sousa&amp;author=A.%20A.%20F.%20L.%20N.%20Queiroz&amp;author=S.%20V.%20M.%20A.%20Lima&amp;volume=36&amp;issue=12&amp;publication_year=2020&amp;pages=e00202420&amp;pmid=33237252&amp;doi=10.1590/0102-311X00202420&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0046">
<cite>

Spieldenner, A.

2016. “PrEP Whores and HIV Prevention: The Queer Communication of HIV Pre‐Exposure Prophylaxis (PrEP).” Journal of Homosexuality
63, no. 12: 1685–1697. 10.1080/00918369.2016.1158012.
</cite> [<a href="https://doi.org/10.1080/00918369.2016.1158012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26930025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Homosexuality&amp;title=PrEP%20Whores%20and%20HIV%20Prevention:%20The%20Queer%20Communication%20of%20HIV%20Pre%E2%80%90Exposure%20Prophylaxis%20(PrEP)&amp;author=A.%20Spieldenner&amp;volume=63&amp;issue=12&amp;publication_year=2016&amp;pages=1685-1697&amp;pmid=26930025&amp;doi=10.1080/00918369.2016.1158012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0047">
<cite>

Ssentongo, P.
, Heilbrunn E. S., Ssentongo A. E., et al. 2021. “Epidemiology and Outcomes of COVID‐19 in HIV‐Infected Individuals: A Systematic Review and Meta‐Analysis.” Scientific Reports
11, no. 1: 6283. 10.1038/s41598-021-85359-3.
</cite> [<a href="https://doi.org/10.1038/s41598-021-85359-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7973415/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33737527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Epidemiology%20and%20Outcomes%20of%20COVID%E2%80%9019%20in%20HIV%E2%80%90Infected%20Individuals:%20A%20Systematic%20Review%20and%20Meta%E2%80%90Analysis&amp;author=P.%20Ssentongo&amp;author=E.%20S.%20Heilbrunn&amp;author=A.%20E.%20Ssentongo&amp;volume=11&amp;issue=1&amp;publication_year=2021&amp;pages=6283&amp;pmid=33737527&amp;doi=10.1038/s41598-021-85359-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0048">
<cite>

Torres, T. S.
, Hoagland B., Bezerra D. R. B., et al. 2021. “Impact of COVID‐19 Pandemic on Sexual Minority Populations in Brazil: An Analysis of Social/racial Disparities in Maintaining Social Distancing and a Description of Sexual Behavior.” AIDS and Behaviour
25, no. 1: 73–84. 10.1007/s10461-020-02984-1.</cite> [<a href="https://doi.org/10.1007/s10461-020-02984-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7394046/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32737817/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS%20and%20Behaviour&amp;title=Impact%20of%20COVID%E2%80%9019%20Pandemic%20on%20Sexual%20Minority%20Populations%20in%20Brazil:%20An%20Analysis%20of%20Social/racial%20Disparities%20in%20Maintaining%20Social%20Distancing%20and%20a%20Description%20of%20Sexual%20Behavior&amp;author=T.%20S.%20Torres&amp;author=B.%20Hoagland&amp;author=D.%20R.%20B.%20Bezerra&amp;volume=25&amp;issue=1&amp;publication_year=2021&amp;pages=73-84&amp;pmid=32737817&amp;doi=10.1007/s10461-020-02984-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0049">
<cite>
U.S. Food and Drug Administration
. 2001. Drug Approval Package: VIREAD (Tenofovir Disoproxil Fumarate) Tablets. U.S. Department of Health and Human Services. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-356_Viread.cfm" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21‐356_Viread.cfm</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?U.S.%20Food%20and%20Drug%20Administration%20.%202001.%20Drug%20Approval%20Package:%20VIREAD%20(Tenofovir%20Disoproxil%20Fumarate)%20Tablets.%20U.S.%20Department%20of%20Health%20and%20Human%20Services.%20https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21%E2%80%90356_Viread.cfm." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0050">
<cite>
U.S. Food and Drug Administration
. 2003. Drug Approval Package: Emtriva (Emtricitabine) 200 Mg Tablets. U.S. Department of Health and Human Services. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021500_emtriva_toc.cfm" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021500_emtriva_toc.cfm</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?U.S.%20Food%20and%20Drug%20Administration%20.%202003.%20Drug%20Approval%20Package:%20Emtriva%20(Emtricitabine)%20200%20Mg%20Tablets.%20U.S.%20Department%20of%20Health%20and%20Human%20Services.%C2%A0https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021500_emtriva_toc.cfm." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0051">
<cite>
U.S. Food and Drug Administration
. 2006. Drug Approval Package: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) Tablets. U.S. Department of Health and Human Services. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021752s000_TruvadaTOC.cfm" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021752s000_TruvadaTOC.cfm</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?U.S.%20Food%20and%20Drug%20Administration%20.%202006.%20Drug%20Approval%20Package:%20Truvada%20(Emtricitabine%20and%20Tenofovir%20Disoproxil%20Fumarate)%20Tablets.%20U.S.%20Department%20of%20Health%20and%20Human%20Services.%20https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021752s000_TruvadaTOC.cfm." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0052">
<cite>
U.S. Food and Drug Administration
. 2016. Drug Approval Package: Descovy (Emtricitabine/Tenofovir Alafenamide). U.S. Department of Health and Human Services. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208215Orig1_toc.cfm" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208215Orig1_toc.cfm</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?U.S.%20Food%20and%20Drug%20Administration%20.%202016.%20Drug%20Approval%20Package:%20Descovy%20(Emtricitabine/Tenofovir%20Alafenamide).%20U.S.%20Department%20of%C2%A0Health%20and%20Human%20Services.%20https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208215Orig1_toc.cfm." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0053">
<cite>

Verburgh, M. L.
, van der Valk M., Rijnders B. J. A., Reiss P., and Wit F. W. N. M.. 2023. “No Association Between Use of Tenofovir Disoproxil Fumarate, Etravirine, or Integrase‐Strand Transfer Inhibitors and Acquisition or Severe Outcomes of SARS‐CoV‐2 Infection in People With HIV in the Netherlands.” AIDS
37, no. 9: 1481–1486. 10.1097/qad.0000000000003577.
</cite> [<a href="https://doi.org/10.1097/qad.0000000000003577" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10328501/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37395254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=No%20Association%20Between%20Use%20of%20Tenofovir%20Disoproxil%20Fumarate,%20Etravirine,%20or%20Integrase%E2%80%90Strand%20Transfer%20Inhibitors%20and%20Acquisition%20or%20Severe%20Outcomes%20of%20SARS%E2%80%90CoV%E2%80%902%20Infection%20in%20People%20With%20HIV%20in%20the%20Netherlands&amp;author=M.%20L.%20Verburgh&amp;author=M.%20van%20der%20Valk&amp;author=B.%20J.%20A.%20Rijnders&amp;author=P.%20Reiss&amp;author=F.%20W.%20N.%20M.%20Wit&amp;volume=37&amp;issue=9&amp;publication_year=2023&amp;pages=1481-1486&amp;pmid=37395254&amp;doi=10.1097/qad.0000000000003577&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0054">
<cite>

Vernazza, P.
, Hirschel B., Bernasconi E., and Flepp M.. 2008. “Les Personnes Seropositives ne Souffrant d’aucune Autre MST et Suivant un Traitement Antiretroviral Efficace ne Transmettent pas le VIH par voie Sexuelle.” Bulletin des Medecins Suisses
81: 165–169.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Bulletin%20des%20Medecins%20Suisses&amp;title=Les%20Personnes%20Seropositives%20ne%20Souffrant%20d%E2%80%99aucune%20Autre%20MST%20et%20Suivant%20un%20Traitement%20Antiretroviral%20Efficace%20ne%20Transmettent%20pas%20le%20VIH%20par%20voie%20Sexuelle&amp;author=P.%20Vernazza&amp;author=B.%20Hirschel&amp;author=E.%20Bernasconi&amp;author=M.%20Flepp&amp;volume=81&amp;publication_year=2008&amp;pages=165-169&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0055">
<cite>

Young, I.
, and Boydell N.. 2023. “'Don't Lose it on the Bus!': Casting the Normative Biosexual Citizen in Early Scottish Pre‐exposure Prophylaxis Provision.” Sociology of Health &amp; Illness
45, no. 5: 1046–1062. 10.1111/1467-9566.13632.
</cite> [<a href="https://doi.org/10.1111/1467-9566.13632" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7616225/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36920962/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sociology%20of%20Health%20&amp;%20Illness&amp;title='Don't%20Lose%20it%20on%20the%20Bus!':%20Casting%20the%20Normative%20Biosexual%20Citizen%20in%20Early%20Scottish%20Pre%E2%80%90exposure%20Prophylaxis%20Provision&amp;author=I.%20Young&amp;author=N.%20Boydell&amp;volume=45&amp;issue=5&amp;publication_year=2023&amp;pages=1046-1062&amp;pmid=36920962&amp;doi=10.1111/1467-9566.13632&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="shil70078-bib-0056">
<cite>

Zablotska, I. B.
, Prestage G., de Wit J., Grulich A. E., Mao L., and Holt M.. 2013. “The Informal Use of Antiretrovirals for Preexposure Prophylaxis of HIV Infection Among Gay Men in Australia.” Journal of Acquired Immune Deficiency Syndromes
62, no. 3: 334–338. 10.1097/QAI.0b013e31827e854a.
</cite> [<a href="https://doi.org/10.1097/QAI.0b013e31827e854a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23187947/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Acquired%20Immune%20Deficiency%20Syndromes&amp;title=The%20Informal%20Use%20of%20Antiretrovirals%20for%20Preexposure%20Prophylaxis%20of%20HIV%20Infection%20Among%20Gay%20Men%20in%20Australia&amp;author=I.%20B.%20Zablotska&amp;author=G.%20Prestage&amp;author=J.%20de%20Wit&amp;author=A.%20E.%20Grulich&amp;author=L.%20Mao&amp;volume=62&amp;issue=3&amp;publication_year=2013&amp;pages=334-338&amp;pmid=23187947&amp;doi=10.1097/QAI.0b013e31827e854a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ol></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Research data are not shared.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Sociology of Health &amp; Illness are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1111/1467-9566.70078"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/SHIL-47-0.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (448.6 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374566/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374566/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374566%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374566/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374566/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374566/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40847916/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374566/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40847916/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374566/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374566/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="gGZQFEVe09QrKK1DfRNz7IB36rAH01eyOnMDJQK7WHfUiMrIPfWzHsr0j1qdFOcn">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
